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Previous studies from the HIV Vaccine Development Group at the University of Cape Town 
have reported that immunisation with recombinant modified vaccinia Ankara (SAAVI MVA-C) or 
DNA prime and Pr55 Gag virus-like particle (VLP) boost based on HIV-1 subtype C are able to 
successfully induce vaccine specific responses in Chacma baboons. The aim of the current 
study was to characterise the T cell memory phenotype distribution in peripheral mononuclear 
cells (PBMCs) isolated from Chacma baboons vaccinated with SAAVI MVA-C/VLP and 
DNA/VLP prime-boost vaccination regimens by flow cytometry. 
 
 In order to achieve the above aim, cross-reactive antibodies were investigated in various 
combinations using 4-colour flow cytometry to select a combination of two antibodies to 
accurately delineate naïve and memory T cells. The selected combination was further 
investigated for functional capacity (IFN-γ and IL-2 production) in response to staphylococcus 
enterotoxin B (SEB) stimulation and expression of a marker of T cell maturation (CD45RA) in 
order to assess its suitability for use in this study. On confirming the validity of these markers in 
the Chacma baboon model, a seven colour flow cytometry panel was then developed and 
optimised to evaluate vaccine specific T cell memory recall responses in vaccinated baboons 
primed with SAAVI MVA-C and boosted with VLP (n=3) or DNA prime and boosted with VLP 
(n=5) or vaccinated with VLP only (n=2). The combined cytokine production (TNF-α, IFN-γ and 
IL-2) by T cells and memory phenotype were then determined using flow cytometry analysis.  
The anti-CD28 and anti-CD95 combination showed the best delineation of central memory 
(Tcm; CD28+CD95+) and effector memory (Tem; CD28-CD95+) populations from the naïve T 
cells (CD28+CD95-) compared to the CD45RA/CD27 and CD95/CD27 combinations which 
were also tested.  The memory subsets delineated by the CD28 and CD95 marker combination 
were further characterised. CD45RA expression was detected on a large percentage (>80%) of 
the naïve CD4 and CD8 cells and minimally (<10%) on CD4 Tem cells. However, 30-40% of 
Tcm and Tem CD8 cells expressed CD45RA. It was observed that the CD4+ and CD8+ Tcm 
cells expressed higher levels of IL-2 (10-15%) compared to Tem (2-6%) while the reverse was 
observed for IFN-γ expression (10-15% for Tem compared to 5-8% for Tcm). In contrast, less 














Vaccine specific cytokine responses peaked four weeks after VLP boost in both MVA/VLP and 
DNA/VLP vaccinations. At this time, Gag-specific CD4+ cells from MVA/VLPs prime-boost 
animals were significantly skewed towards a Tcm phenotype (80-90%) of total cytokine 
responses compared to the Tem phenotype (10-20%). In these animals, Gag-specific CD8+ 
Tem comprised 30-40% of total cytokine responses. A similar memory distribution profile of 
Gag-specific CD4+ cells in DNA/VLPs was observed. Gag-specific CD8+ cells were distributed 
between Tcm (~60%) and Tem (~40%) phenotypes. The memory distribution profile of Gag-
specific CD4+ cells was detectable in the MVA/VLPs and DNA/VLPs group 24 weeks and 8 
weeks after the VLP boost respectively. The proportion of CD4+ T cells in the VLP only group 
was predominantly of the Tcm phenotype (70-80%). However, in CD8+ T cells the Tem 
phenotype comprised 50-70% of the total vaccine specific memory response. 
 
The results demonstrate that anti- CD28 and -CD95 antibodies are suitable for the delineation of 
baboon Tem and Tcm cells since these subsets exhibited the expected functional 
characteristics observed in healthy rhesus macaques. The skewing of vaccine specific CD4+ T 
cell responses in both vaccine regimens towards the Tcm phenotype imply that these vaccines 
have the capacity to generate Tcm pools associated with rapid differentiation and replenishment 
of vaccine specific effector cells. In addition, the presence of functional CD8+ effector memory T 
cells observed here, have been previously associated with the control of infection at the portals 
of viral entry. 
 
This study indicates the suitability of CD28 and CD95 for inclusion in flow cytometry panels to 
investigate T cell memory in baboon PBMCs. A multicolour flow cytometry panel for analysis of 
vaccine specific T cell memory was also developed. In addition, this study demonstrates the 
generation of vaccine specific, functional and long-lived Tcm and Tem in T lymphocytes of 
baboons vaccinated with SAAVI MVA-C/VLP and DNA/VLP prime-boost vaccination regimen. 
Taken together, this study demonstrates the potential inclusion of these candidate vaccines in 
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1. LITERATURE REVIEW 
 
Based on recent estimates, Sub-Saharan Africa remains the region most heavily affected by 
HIV and accounts for more than two thirds of infections worldwide (UNAIDS, 2012a). 
Unfortunately, it is projected that the number of infected people will continue to increase unless 
a novel and effective means of intervention is found. The search for an effective human 
immunodeficiency virus (HIV) vaccine capable of preventing the transmission and spread of 
infection was started almost 20 years ago. To date there have been no reports of a vaccine 
which offers total protection from HIV infection.  
However, during this time, there have been numerous breakthroughs in the field of HIV vaccine 
research, and it now widely accepted that in order for a protective vaccine to exist, there is a 
dire need to further understand the interactions between the virus and the host immune 
response. In addition, innovative and improved vaccine platforms need to be examined in terms 
of how to optimally deliver HIV immunogens to the host to generate robust, long-lived and safe 
immune responses. 
This chapter will briefly review the virology, infection and immunopathogenesis of HIV type 1 
(HIV-1) and discuss the ongoing research and challenges faced in the field of HIV-1 vaccine 
development. This chapter will also highlight candidate HIV-1 vaccines developed by the HIV-1 
Vaccine Development Group based at the University of Cape Town (UCT). Finally, this chapter 
will address the rationale, aim and objectives of this study. 
1.1. HIV virology  
1.1.1. HIV epidemiology and disease burden in a South African context  
 
Since the first recognised case of Acquired Immunodeficiency Disease Syndrome (AIDS) in 
1981 and the discovery of HIV as the virus responsible for AIDS in 1983, more than 60 million 
people have contracted HIV and almost 30 million have died of HIV-related causes (Girard et 
al., 2011). At the end of 2011, there were 34 million people living with HIV and 1.7 million AIDS 
related deaths were reported (UNAIDS, 2012a). An alarming 69% of the people living with HIV 
are from sub-Saharan Africa (UNAIDS, 2012a). In summary, the total number of HIV related 
deaths in adults and children in this region reportedly contributed 71% of the global HIV related 
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subtype C is the predominant pathogenic strain of the virus (UNAIDS, 2012b), are most at risk 
of infection and contribute to 59% of all people living with HIV. In South Africa, there are 5.6 
million people living with HIV and a total of 270, 000 AIDS related deaths were reported at the 
end of 2011 (UNAIDS, 2012b). The improved treatment policies and increased roll of ARVs has 
helped to considerably reduce incidence rates from 2003, however the HIV prevalence rate in 
adults remains the highest in the world at 17.3% with reports of 380, 000 newly infected South 
Africans at the end of 2011 alone (UNAIDS, 2012b). Therefore, there is still a need to find an 
integrated approach to the treatment and prevention of HIV which comprise of an effective, safe 
and widely available prophylactic vaccine.  
1.1.2. Viral diversity of HIV  
 
HIV belongs to the genus Lentivirus in the family of enveloped ribonucleic acid (RNA) viruses 
called Retroviridae. The viruses classified in this family are usually associated with the ability to 
induce slow, progressive infections with long-term symptoms and latency periods.  HIV is 
thought to have originated from the zoonotic transmission of Simian Immunodeficiency Virus 
(SIV) from infected nonhuman primates (NHPs) in Central or Western Africa (Gao et al., 1999).  
The virus was transmitted to humans early in the twentieth century and has since evolved into 
an effective, virulent human pathogen (Korber et al., 2000). 
Two lineages of HIV namely HIV type 1 (HIV-1) which is made up of groups M, N, O and P and 
HIV type 2 (HIV-2) made up of groups A to H have been defined. These two lineages differ 
considerably in terms of both species of origin and relative virulence. HIV-1 is by far the more 
virulent of the two lineages and HIV-1 group M is responsible for the current global HIV 
pandemic. Infection with HIV-1 group O is most prevalent in Western and Central Africa (Simon 
et al., 1998) and HIV-1 group N and P infection has been reported in Cameroon (Ayouba et al., 
2001, Vallari et al., 2011). Both HIV-1 group M and group N are thought to have originated from 
SIV infection in chimpanzee subspecies Pan troglodytes troglodytes SIV (SIVcpz) endemic to 
central Africa (Gao et al., 1999) while the HIV group P is suggested to have originated from the 
SIV infections (SIVgor) in gorillas (Gorilla gorilla gorilla) from West Africa (Vallari et al., 2011).  
There is also a high level of diversity within each group leading to a further division of the virus 
into subtypes (also called clades). In particular, group M, can be further subdivided into ten 
recognised phylogenetic subtypes, or clades (A to K) (Buonaguro et al., 2007). The level of 
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diversity is as high as 8-17% (Korber et al., 2001). Furthermore, the immune response to HIV 
infection is the driving force of viral evolution and escape mutation. The formation of escape 
mutants (albeit at the cost of viral fitness) and high viral diversity is a major challenge for the 
development of an effective HIV vaccine.   
1.1.3 Structural and genomic organization of HIV-1 
 
Like most Lentiviruses, HIV is capable of converting its positive sense, single-stranded RNA 
(ssRNA) into double stranded deoxyribonucleic acid (dsDNA). This is achieved by the 
integration of the HIV particles to host cells and the action of reverse transcriptase encoded 
within the viral genome. The newly synthesised viral DNA is then integrated into the host cellular 
DNA by host co-factors and viral intergrase which is encoded within the viral particle (Smith et 
al., 2006).  The integrated virus either becomes latent (Levy et al., 1993) which ensure the virus 
and infected cells avoid detection by the immune system. Alternatively, the virus produces new 
RNA genomes through transcription and the viral proteins produced are released from the cell 
as new virus particles that go on to infect other cells.  
1.1.3.1 Structural organisation and fundamental proteins of HIV-1  
 
 The spherical shaped HIV particle is 120nm in diameter and is composed of a bi-layer lipid 
envelope surrounding a matrix which contains viral proteins. The genome of HIV is made up of 
two copies of ssRNA comprising genomic information required for the replication, maturation 
and structure of HIV and is surrounded by a conical capsid. The capsid contains p24 protein 
which is enclosed within a nucleocapsid. Viral proteins enclosed within the capsid such as 
Reverse transcriptase (RT) and Integrase are closely associated to the RNA genome and are 
fundamental to the development and pathogenesis of both virions and mature virus (Bieniasz, 
2009, Sundquist et al., 2012).  
 In addition, other proteins such viral inhibitory factor (Vif) which disrupts the entry of the anti-
viral host protein known as apolipoprotein B mRNA-editing, enzyme-catalytic polypeptide like 3 
(APOBEC3) and enhances HIV-1 replication (Schrofelbauer et al., 2004). Other proteins such 
as viral protein R (Vpr), negative fact (Nef) and protease are also present within the capsid.  Vpr 
is a key regulator of maturation of the virion and is required for virus replication and infection of 
non-dividing host immune cells such as macrophages (Pandey et al., 2009). Nef is expressed 
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host T cell activation and drives chronic viral replication in these activated cells during infection 
(Das and Jameel, 2005), whilst HIV protease functions to cleave newly synthesised viral 
polyproteins to form appropriate structure and regulatory proteins in new virions (Kohl et al., 
1988). The lipid envelope surrounding the matrix contains glycoproteins (extracellular gp120 
and trans-membrane gp41). Gp120 and gp41 glycoproteins are responsible for the fusion of the 
virus to host cells (Wyatt et al., 1998) and have therefore been targeted for anti-viral vaccine 
development. 
1.1.3.2 The genome of HIV-1 comprises structural and regulatory genes 
 
Lentiviruses that infect primates have numerous accessory genes used to evade the host 
immune response (Kirchhoff, 2010).The genome of HIV is composed of three structural and six 
regulatory genes which encode nine open reading frames. The proviral form of HIV-1 is flanked 
by two long terminal repeat (LTR) sequences (Muesing et al., 1985). 
The structural genes namely gag, pol, and env encode structural proteins for new virus 
particles (Figure 1.1).  The gag gene encodes the Gag polypotrein which is eventually 
processed into a range of structural proteins such as p17, p24, p6 and p7.  
The viral enzymes reverse transcriptase, integrase and protease are encoded for by the pol 
gene and the env gene codes for the gp160 protein that is enzymatically processed during 
virion maturation into gp120 and gp41. These proteins are the structural components of the 
Env protein.   The trans-activator of transcription (tat) gene is a regulatory gene encoding for 
Tat , which is in turn a critical viral protein that enhances both the transcription of viral RNA into 
dsDNA (Debaisieux et al., 2012) and infection of host bystander CD4+T cells (Campbell et al, 
2004). The gene regulator of virion expression (rev) is responsible for the regulation of viral 
transcription. Additional regulatory genes such as viral protein R (vpr), viral infectivity factor 
(vif), viral protein U (vpu) and negative regulator protein (nef) encode for proteins responsible 
for viral replication in non-dividing host cells such as macrophages, evading host immune 


























Figure 1.1 Structural organisation of HIV-1 genome. The genome of HIV-1 is approximately 9087 base pairs in length, contains structural and 
regulatory genes and is flanked by long terminal repeat (LTR) sequences on either end. Structural genes such as gag and env encode for core 
and envelope proteins respectively and the remaining genes (pol, vif, vpr, tat, vpu, rev and nef) are associated with the regulation of viral 
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1.2 Immunopathogensis of HIV-1  
1.2.1 HIV-1 infection of target cells 
 
Transmission of HIV-1 infection occurs through sexual intercourse; exposure to infectious body 
fluids; and vertical infection from mother-to-child during pregnancy, delivery or breast-feeding. In 
about 80% of infections, only a single virus (founder virus) is transmitted across the mucosa 
(Keele and Derdeyn 2009; Abrahams et al., 2009). The virus preferentially infects 
gastrointestinal and genital mucosa tissues in which a high frequency of activated CD4+ T cells 
can be found (Brenchley and Douek 2008). 
 
 These T lymphocytes, express the surface molecule CD4, the receptor for HIV-1 binding and 
co-receptors for HIV-1 binding such as chemokine co-receptor 5 (CCR5) or the C-X-C 
chemokine receptor type 4 (CXCR4) (Douek et al., 2002) and are thus the main target cells of 
HIV-1 infection. In addition, a number of other cellular proteins have been associated with HIV-1 
binding and these molecules are found on B cells, dendritic cells and macrophages. These 
molecules include CD21 a surface molecule expressed on B cells (Moir et al., 2000), the C type 
lectins such as DC-SIGN (Hioe et al. 1998), intracellular adhesion molecules (ICAMs) (Bounou 
et al., 2002), leukocyte function-associated antigens (LFAs) and α4β7 integrin (Arthos et al., 
2008).  As such, HIV-1 is also able to infect B cells, dendritic cells (DCs) (Steinman et al., 2003) 
and macrophages (Li et al., 1999). The binding of HIV-1 to its target cells, particularly the CD4+ 
T cells, is reviewed in Lever and Jeang (2011). 
 
In summary, the gp120 protein on the viral surface first binds to surface CD4 and co-receptors 
CCR5 or CXCR4. This binding releases gp41 and allows for the fusion of the viral envelope with 
the host cell membrane. The viral core is then released into the cytoplasm of the host cell. This 
is followed by the release of viral RNA from the viral core. The ssRNA is then reverse- 
transcribed into double stranded cDNA by the viral reverse transcriptase enzyme. The newly 
formed dsDNA is then translocated into the host nuclease and is integrated into the host cell 
genome to form a provirus with the assistance of viral integrase and Vpr. T cell activation then 
perpetuates proviral transcription (Stevenson et al., 1990). The first RNA transcripts that are 
processed and spliced into messenger RNA (mRNA) encoding for regulatory viral proteins Tat 
and Rev which enhances transcription of viral RNA and the cytoplasmic transport of viral RNA 










Chapter 1  
9 
 
Gag, Pol and Env which together with the viral genomic material are then assembled to form 
new viral particles (Sundquist and Krasslich, 2012). The newly formed viral particles bud from 
the host cells and are released to infect more target cells. This leads to the depletion of target 
cells and is followed by the subsequent dysfunction of the immune system. In the absence of 
antiretroviral therapy (ART), HIV-1 replication occurs at exponential rates, rapidly depleting both 
infected and uninfected (bystander) CD4+ T cells through HIV proteins such as Env, Tat and 
Nef that are secreted extracellularly (Finkel et al., 1995).  
1.2.2. Acute infection  
 
The typical course of untreated HIV-1 infection is initiated with an acute phase of infection which 
commences 2 to 4 weeks after transmission (Figure 1.2). During this phase, most individuals 
develop acute HIV syndrome, characterised by fever, lymphadenopathy and high plasma 
viraemia (Gurunathan et al., 2009). The acute phase of HIV infection is also associated with 
high rates of HIV replication with peak viraemia achieved approximately 4 weeks after infection 
(Piatak et al., 1993, Little et al., 1999) and a steady decline in CD4+ T cells. The host immune 
response to HIV-1 is present early during the initial infection when viral replication is still largely 
isolated in mucosal tissues.   
1.2.2.1 Dendritic cells and natural killer cells during acute HIV-1 infection 
During the acute phase of HIV-1 infection, CD4+ T cell depletion is amplified and this coincides 
with the release of acute phase proteins such as serum amyloid A and pro-inflammatory 
cytokines such as IL-15 and type I interferons (as reviewed by McMicheal et al., 2010) by 
dendritic cells. In addition C-X-C chemokine ligand 10 (CXCL10) and other soluble factors such 
as lipopolysaccharide (LPS) are also released. 
The onset of these early cytokines and chemokines corresponds to an increase in viraemia 
(Figure 1.3). During this time, the number of circulating dendritic cells (DCs) are also reduced 
(Killian et al., 2006) and natural killer (NK) cells become activated (Alter et al., 2007). Human 
DCs, either in the form of plasmacytoid DCs (pDCs) or myeloid CD11c+ conventional DCs 
(mDCs) play a central role in virus detection, the initiation of adaptive immune responses and 
viral elimination. Specific pattern recognition receptors (PRRs) expressed on DCs such as the 
C-type lectins and toll-like receptors (TLRs) are able to detect free viruses and virally infected 
cells (including HIV-1 infected cells) in the periphery and become activated (Kawai and Akira, 
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the early adaptive immune responses by the production and release of IFN α. Furthermore, type 
I IFNs released by pDC initiate the proliferation and cytotoxicity of NK cells (Gerosa et al., 
2005). 
 
During acute HIV infection, NK cells induce antiviral response by the production of pro-
inflammatory cytokines and lysis of infected cells (Biron et al., 1999; Altfeld et al., 2011). 
However, as mentioned above, NK cell activation requires the release of cytokines from DCs.  
Studies have shown that mDCs release IL-12 and IL-18 which promotes the production of IFN-γ 
by NK cells in vitro (O’Leary et al, 2006; Borg et al., 2004).  
 
Figure 1.2. T cell dynamics during the typical phases of untreated HIV-1 infection. During acute 
HIV-1 infection, the number of CD4+ T cells (green line) decline as a result of increasing viral load (red 
line). Soon after infection, the number of CD8+ T cells increase (blue line) in an attempt to control 
viraemia. In effect, the viral load decreases and reaches a viral set point which is maintained during the 
clinical latency phase of infection. During this stage, CD4+ T cells are replenished, but only to a level 
lower than before infection. However, viral escape from CD8+ T cells and antibody responses (not 
shown) occurs and viral load increases followed by the depletion of CD4+ and CD8+ T cells. This phase 
of infection characterised by immune deterioration is clinically defined as AIDS. (Adapted from Sewell et 
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1.2.2.2 Adaptive immune responses during acute infection 
i. Antibody responses during the acute phase of HIV-1 infection 
 
The initial production of HIV-1 specific antibodies (occurs around 5 days following the onset of 
cytokine release) is directed towards the non-neutralising sites of gp41 and does not select for 
viral escape (Moore et al., 2006). The antibodies directed towards the founder virus are capable 
of non-neutralising activity such as antibody-dependent cell-mediated cytotoxicity (ADCC) and 
antibody-dependent cell-mediated viral inhibition (ADCVI), are only detectable 3 months after 
infection has occurred. However, by the time these antibodies are generated, the virus has 
already established infection and can mutate to avoid binding to these early antibodies 
altogether (Wei et al., 2003; Moore et al., 2006). 
ii. T cell responses during acute infection 
 
As the plasma viral load increases during acute infection, the ratio of  CD4:CD8 T cells is 
inverted with CD8+ T cells expanding with viral load and CD4+ T cells declining. The first HIV-1 
specific CD8+ T cell responses are detected just before peak viraemia is established. This 
response selects for escape mutant epitopes or regions of the virus that mutate at the cost of 
viral fitness (Goonetilleke et al., 2009).  Evidence suggests that CD8+ T cells exert direct 
cytotoxic effects on infected cells, suppress viral replication via cytokines, chemokines and other 
mediators or inhibit viral entry by soluble factors as reviewed by Freel et al. (2011). 
 The initial expansion of HIV specific CD8+ T cells during the acute phase of infection is 
followed by a decline in viral load over several weeks. This transient decline in viral load is due 
to a robust immune response driven by these activated CD8+ T cells. It has also been 
suggested that the decline in viral load could also result from the loss of susceptible CD4+ 
target cells at the site of HIV-1 infection and accounts for the limited CD4+ HIV-specific 
responses (Brenchley et al., 2004). The immune pressure exerted by the host leads to an 
establishment of a stable level of viral load, (known as viral set point) (Piatak et al, 1993) and is 
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1.2.3. Clinical latency and viral escape 
 
Once viral set point is established, untreated HIV infected individuals almost always progress 
toward chronic infection known as clinical latency (Figure 1.2.) which can persist for around 2 to 
20 years. This phase of infection occurs approximately 6 months following acute infection during 
which virus levels in the plasma reach a set point below 20 000 RNA copies/ml. Within 10 days 
following CD8 expansion, the virus has already generated new mutants capable of CD8 escape. 
At this stage viral reservoirs are established. It takes up to 80 days for the development of early 
autologous virus specific neutralising antibodies. The virus once again escapes just weeks after 
the antibodies are detectable in plasma samples.  
1.2.4. The development of AIDS 
 
Eventually, infection spreads to the peripheral lymphoid organs and CD4+CCR5+ T cells are 
progressively depleted (Brenchley and Douek, 2008). Intervention from ARVs might impede HIV 
infection and disease progression but HIV-1 has the ability to rapidly establish a reservoir of 
latently infected long-lived resting CD4+ memory T cells (Finzi et al., 1999; Alexaki et al., 2008).  
At this stage, the immune system begins to progressively deteriorate and infected individuals 
become highly susceptible to opportunistic infections (Figure 1.2) (Kitahata et al, 2009). Infected 
individuals at this stage are usually diagnosed with AIDS with a CD4+ below 200 cells/mm3 and 
without treatment these people will eventually die as a result of AIDS related diseases.  
1.2.5. HIV controllers  
 
The vast majority of HIV infected individuals will succumb to AIDS without treatment as a result 
of immune deterioration and opportunistic infections. However, some groups of HIV infected 
individuals are able to control infection. One such group known as elite controllers, have the 
ability to spontaneously control viraemia without ARVs and are defined by virologic criteria as 
having low to undetectable viral loads despite being infected for more than two years (Okulicz et 
al., 2009).  The prevalence of this group is less than 1% in the population of infected individuals 
and elite controllers have a reduced risk of AIDS and death.  
Another group of HIV infected individuals defined as long-term nonprogressors (LTNPs)  on the 
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ARVs (as reviewed by Okulicz, 2012). These individuals have low to moderate levels of 
viraemia but have ≥ 500 CD4+ cells/µl. The mechanism responsible for this level of control is 
unclear but both elite controllers and LTNPs are the focus of numerous research efforts to 
identify these mechanisms of spontaneous control (Okulicz, 2012). 
Highly exposed persistently seronegative (HEPS) individuals are groups of individuals that are 
exposed to HIV and despite this, remain HIV-negative in the absence of ARVs. In Kenya and 
The Gambia, HEPS prostitutes have been identified (Fowke et al., 1996; Rowland-Jones et al., 
1995). Although there is evidence of HIV-1 specific CD8+ cytotoxicity in vitro these individuals 
remain HIV-1 negative. It has been shown that in these individuals HIV specific CD8+ 
responses depends on persistent exposure to HIV and is acquired over time (Kaul et al., 2001). 
1.3. The development of an effective HIV-1 vaccine 
1.3.1 The need for an HIV-1 vaccine 
 
The implementation of HAART and improved ARV roll out has ensured a prolonged, relatively 
asymptomatic life for infected individuals and has decreased the incidence of HIV-1. The HIV 
Prevention Trial Network (HPTN) trial known as HPTN 52 concluded that the use of ARTs to 
reduce the viral load of the infected partner in HIV discordant couples effectively decreased the 
probability of HIV transmission to the uninfected partner (Cohen et al., 2012). Improved ART 
coverage has also been reported to reduce the number of HIV related deaths and improved the 
life expectancy of adults in populations with high HIV prevalence (Bor et al., 2013). Recent 
reports have also demonstrated that the risk of HIV acquisition decreases substantially as the 
coverage of ART increases which implies that HIV negative individuals that live in areas with 
high ART coverage are less at risk of HIV infection compared to those in areas with low or no 
ART coverage (Tanser et al., 2013).  
Currently, there are ongoing studies aimed at evaluating the effectiveness of post exposure 
prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) as part of treatment and prevention 
policies. There has also been recent improvements and significant advancement in anti-viral 
microbicides particularly Tenofovir gel containing ARVs which has shown to reduce infection of 
HIV-1 by 38% in women in the CAPRISA -004 study (Abdool et al., 2010). However, in regions 
such as South Africa, with high HIV prevalence, there are many social, cultural and economic 
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adherence to treatment is a major hindrance to the success of these treatment options. The 
phase 2B Vaginal and Oral Interventions to Control Epidemic (VOICE) trial, known as the 
Microbicide Trial Network (MTN)-003 trial, was designed to assess the safety and efficacy of 
oral and vaginal PrEP (including tenofovir). The results of this study showed no significant 
decline in HIV acquisition in participants (van der Straten et al., 2012). These results were in 
contrast to what was found in terms of efficacy in the CAPRISA-004 study. It is believed that the 
lack of participant adherence to the daily dosage of the treatment is a major contributing factor 
to these conflicting results (van der Straten et al., 2012).   
Apart from PrEP treatment, there are promising results from studies investigating male 
circumcision as a method of HIV-1 prevention. To date, studies investigating the prevention of 
HIV infection by circumcision conducted in South Africa, Kenya and Uganda showed a 
significant decline in HIV incidence of 60%, 53%, and 51% respectively in circumcised versus 
uncircumcised participants (Auvert et al., 2005; Bailey et al., 2007; Gray et al., 2007). The 
protective effects of circumcision were sustained for up to 66 months in circumcised men in 
Kenya and 5 years in Ugandan men (Bailey et al. 2010; Gray et al., 2012) and it has been 
proposed that circumcision performed in infancy can offer further protection from HIV. However, 
there are many concerns arising from this including the cost, safety concerns during 
circumcision and the risk of circumcised men engaging in unprotected sex.  
In light of these concerns, together with the challenges of non-adherence to PrEP and ARVs; 
the possibility of new drug resistance HIV strains surfacing and the safety concerns of using 
ARVs in a setting with a high prevalence of co-infections, the development of an effective 
prophylactic HIV-1 vaccine is still viewed as the most cost-effective means of preventing HIV-1 
transmission. However, the development of an effective HIV-1 vaccine poses numerous 
challenges.  
The correlates of protection for HIV vaccines remain unclear despite the advances in the 
understanding of the pathogenesis of the virus. In the past, the development of potent antibody 
responses has been the hallmark of successful vaccines against numerous diseases (Plotkin, 
2010). However, one of the most challenging aspects of HIV-1 vaccine design is the 
development of an immunogen to successfully elicit broadly neutralizing antibodies against a 
broad spectrum of HIV-1 isolates. In addition, there are other challenges that oppose the 
progression of HIV vaccine development, such as the inherent ability of the virus to escape from 
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host immune system to co-ordinate effective clearance of the infection (Walker and Burton, 
2008; Barouch, 2008).    
1.3.2. Characteristics of an effective HIV-1 vaccine 
 
Ideally, an HIV vaccine should mediate both the production of antibodies and T cell immune 
responses (Mascola et al., 2005; Watkins et al., 2008). Studies regarding viral control in HIV-1 
infected individuals, nonhuman primate models of disease and increasing evidence from clinical 
HIV vaccine trials have provided researchers with an understanding of some of the 
immunological responses that an effective HIV-1 vaccine should induce. 
The development of vaccines to induce antibody responses capable of neutralisation usually 
includes envelope proteins as immunogens. These vaccines aim to prevent the binding of HIV-1 
to target cells and inhibit infection in this manner. T cell based vaccines on the other hand, 
induce cell mediated immune responses to combinations of viral regulatory proteins such as 
Gag, RT or Nef which are included as vaccine immunogens. An ideal T cell based vaccine 
(Figure 1.3), should have the ability to reduce viral replication, limit the infection of CD4+ T cells 
and delay disease progression during the acute phase of infection in order to minimise the risk 








Figure 1.3. Goal of T cell based HIV-1 vaccines. Following untreated infection, HIV-1 replication occurs 
and the viral load (measured as number of viral RNA copies/ml) continues to increase until peak viraemia 
is reached. At this stage, the viral load declines to establish a viral set-point and if untreated, this infection 
progresses to AIDS (blue line). An ideal T cell based vaccine (red line) aims to reduce viral replication 
during the acute phase of infection. This in effect controls the infection and prevents transmission. 
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1.3.2.1. Insights from HIV infections and the control of viraemia 
 
Studies of HIV-1 infection demonstrate that transmission from infected individuals to HIV-1 
negative partners is significantly reduced when the viral plasma loads are below 1700 RNA/ml 
in the infected individual (Quinn et al., 2000, Gray et al., 2001). There is evidence from studies 
investigating the immune responses of elite controllers, LTNPs and seronegative individuals 
exposed to HIV infection which demonstrates that T cell responses are responsible for limiting 
viral replication and therefore have the ability to limit infection. These studies have led to the 
understanding of what is required in the design of HIV-1 vaccines. 
As discussed above, the reduction of peak viraemia in acute HIV-1 infection coincides with an 
increase in CD8+ T cells which suggests that CD8+ T cell responses are involved in the control 
of viraemia (Koup et al., 1994; Borrow et al., 1994; Betts et al., 2006). Studies investigating 
LTNPs have found that progression to disease is hindered in the presence of HIV-specific CD8+ 
T cell response and correlates to the reduction of viral replication (Betts et al., 2006; Gea-
Banacloche, 2000). In addition, the maintenance of proliferative, polyfunctional HIV-specific 
CD4+ T cell responses have been associated with long term non-progression (Boaz et al., 
2002). In addition, Duvall et al. (2008) compared the prevalence of polyfunctional CD4+ and 
CD8+ T cells in HIV-1 infected individuals to HIV-2 infected individuals. HIV-2 infected 
individuals exhibit delayed progression to disease and preserved CD4+ T-cell counts close to 
normal levels. The results of this study suggest that there is a higher frequency of polyfunctional 
T cells produced by HIV-2 infected individuals compared to that in HIV-1 infected individuals. 
Cytotoxic T cell mediated responses were also observed in studies investigating seronegative 
sex workers in Nairobi that are exposed to HIV infection and exposed uninfected children born 
to HIV infected mothers (Rowland-Jones et al., 1998; Cheynier et al., 1992).   
The role of CD8+ T cells in the control of infection is not restricted to cytotoxic responses. 
Chronic asymptomatic HIV infected individuals have greater CD8+ non-cytotoxic antiviral 
response compared to symptomatic individuals (Walker et al., 1989, Mackewicz et al., 1994, 
Castelli et al., 2002). Viral entry into CD4+ T cells and macrophages is in part mediated by 
soluble factors such as macrophage inhibitory protein (MIP)-1α, MIP-1 β and regulated and 
normal T cell expressed and secreted (RANTES). These chemokines are ligands for the HIV-1 
co-receptor, CCR5, and inhibit viral replication in CD4+ T cells and macrophages (Cocchi et al. 
1995). Studies indicate that the ability of HIV specific CD8+ T cells to express perforin, 
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associated with control in HIV infected controllers (Hersperger et al., 2010; Migueles et al., 
2002) The role of CD8+ T cells in the control of infection is therefore not restricted to one 
cellular function but rather to the ability of a cell to produce multiple functions (as defined by 
cellular marker such as, CD107a, MIP-1α, IFN-γ, IL-2, TNF-α, and perforin) (Betts et al,. 2006; 
Almeida et al., 2009; Ferre et al, 2009).  
As such, studies of HIV infection and controllers of infection have indicated that CD8+ T cell are 
a necessary component of anti- HIV-1 immune responses and vaccines that induce robust, 
functional HIV-1 specific CD8+ responses are highly sought. Although T cell based vaccines 
may not be able to provide protection from infection, there is evidence to suggest that these 
vaccines should ideally be able to control early viral replication after infection and possibly 
prevent dissemination of the virus into tissues and delay the progression to disease.  
Early studies in LTNP also indicated that neutralising antibody responses were associated with 
viral control (Montefiori et al., 1996). However it has been found in studies investigating HIV-1 
infected individuals that at the time at which broadly neutralising antibody responses are 
present, viral load is higher (Deeks et al., 2006; Pereyra et al., 2008; Doria-Rose and Connors, 
2009). It is suggested that these antibodies are specific to early viral clones. These studies have 
been useful in suggesting that constant antigenic stimulation is required for the production of 
broadly neutralising antibodies.  Recently, broadly cross-reactive neutralising (BN Abs) were 
identified in two long-term HIV-1 infected individuals. These antibodies targeted the Asn 332 
glycan on gp120 which evolved through viral escape mutations (Moore et al., 2012). These BN 
Abs were able to neutralise other escape clones in which the Asn332 glycan was also present. 
This offers hope that BN Abs are still a viable option to reduce and eliminate HIV-1 infection. 
1.3.2.2. Non-human primate models and HIV-1 vaccine development  
i. The use of nonhuman primates as a model for HIV-1 vaccine studies 
The lack of an ideal animal model to test candidate HIV-1 vaccines has been one of the many 
reasons cited to explain the slow progress in developing an effective vaccine. During NHP 
preclinical trials of candidate HIV-1 vaccines, it is possible to determine whether the vaccine has 
the ability to safely induce HIV-1 specific immune responses. These studies can also determine 
the presence of anti-vector immunity and long term protective adaptive and/or antibody 
responses. There is increasing evidence that suggests that a universal preclinical evaluation of 
HIV-1 vaccine candidates will be necessary to ensure accuracy and uniformity between trials. 
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similarity between nonhuman primates and humans. HIV-1 does not infect NHPs and several 
strains of SIV are used to predict the efficacy of HIV vaccines in this model. Both HIV and SIV 
have been theorised to originate from a common ancestor and therefore exhibit numerous 
nucleotide sequence homologies (Meyer et al., 1999). However, SIV differs from HIV-1 in the 
structural and antigenic nature of the Env protein and has limited the reliability of NHP studies of 
vaccine efficacy using SIV challenge. 
This has led to the development of the chimeric virus which is the env gene from HIV expressed 
on SIV backbone referred to as Simian/Human Immunodeficiency virus (SHIV) (Li et al., 1995). 
This has allowed for the evaluation of vaccines containing Env immunogens. SIV infection leads 
to the depletion of CD4+T cells, rapid viral replication and progression to AIDS in most rhesus 
macaques in a similar manner to infection of humans with HIV-1. In addition, some rhesus 
macaques with the MHC class I haplotype profile of Mamu-A*01, Mamu-B*17 and MamuB*08 
exhibit similar levels of control observed in elite controllers or LTNPs in which viral loads are 
almost undetectable in the absence of ARVs (Bontrop and Watkins, 2005).  Based on this, the 
rhesus macaque model is considered useful in HIV-1 studies.      
The NHP model serves as arguably the most useful predictive model of safety and 
immunogenicity of candidate HIV-1 vaccines. The NHP model can also be used to test the 
efficacy of vaccine candidates containing the Env using matched SHIV challenges (Amara et al., 
2002; Polacino et al., 1999). However, the efficacy of candidate HIV vaccines can only be tested 
in Phase 3 clinical trials. 
ii. The relevance of using Chacma baboons as models of HIV-1 vaccine evaluation  
 
Baboon species have been established as important predicator models to measure candidate 
vaccine safety and immunogenicity prior to clinical studies. Most studies have used the olive 
baboon (Papio anubis) or the yellow baboon (Papio cynocephalus) for the evaluation of malaria 
and Schistosoma mansoni vaccine efficacy (Chowdhury et al., 2009; Ahmad et al., 2011). 
These species of baboons have also been used to measure the immunogenicity of HIV-1 
vaccines (Casimiro et al., 2003; Leung et al., 2004). In South Africa, the Chacma baboon (Papio 
ursinus) has also been used to determine the safety and immunogenicity of HIV-1 vaccines 
(Chege et al., 2009; Burgers et al., 2009). Baboons are closely related phylogenetically to 
humans with DNA homology between baboons and humans estimated at 96% (Hixson et al., 
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therefore have the potential to induce similar immune responses and share a broad range of 
cross-reactive T lymphocyte CD antigen repertoires with humans (Perry et al., 2012). In terms of 
preclinical evaluation of vaccines, baboons are widely available in South Africa making vaccine 
development and immunogenicity testing cost effective.  To date, the baboon model has been 
used to evaluate candidate vaccines which are designed to generate neutralizing antibodies 
(Anderson et al., 1989; Stephens et al., 1992; Haigwood et al., 1992), and the ability of vaccines 
to induce cellular immune responses in Chacma baboons (Casimiro et al., 2003; Chege et al., 
2008a; Chege et al., 2008b; Burgers et al., 2009). 
iii. Insights into HIV vaccine development from non-human primate models 
 
To date, NHP models have led to the understanding and analysis of transmission of HIV/SIV 
across mucosal barriers, the establishment of viral reservoirs and latency in hosts, the effect of 
vaccination and challenge via different routes and viral dissemination (as reviewed in Lifson and 
Haigwood, 2012). In addition, NHP models have also allowed for the evaluation of innate and 
adaptive immune responses to vaccination as well as the production of antibodies and are 
invaluable for comparative assessment of candidate HIV-1 vaccines.  
There are also lessons to be learnt for HIV vaccine development from investigating primate 
species with the ability to control SIV replication and pathogenesis. For instance, natural hosts 
of SIV, such as African green monkeys and sooty mangabeys do not develop chronic disease, 
despite viral loads similar to those detected in humans infected with HIV-1 and rhesus 
macaques infected with the SIV (SIVmac) (Liovat et al., 2009). Investigating the molecular 
mechanisms that prevent the onset of chronic diesease may be beneficial in determining the 
type of vaccine responses which could protect against disease progression. 
The importance of HIV-1 specific CD8+ T cells responses has been supported by numerous 
studies in NHPs. Studies investigating the role of CD8+ T cell responses in SIV infected rhesus 
macaques showed that vireamia and viral load increased significantly after CD8+ T cells were 
depleted compared to SIV infected macaques in which CD8+ T cell responses were present 
(Schmitz et al., 1999; Watkins et al., 2008). This confirmed that CD8+ T cells not only limited 
viral replication, but might also have the ability to control infection if they are primed early during 
acute infection before significant CD4+ T cells depletion. More recently, Wong et al. (2010), not 
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macaques, but they also confirmed findings that non cytotoxic CD8+ T cells functions, such as 
the production of cytokines and chemokines, are involved in viral control during infection.  
To date, a number of vectors and vaccination regimens have been evaluated in NHPs. The use 
of T cell based HIV-1 vaccines (such as recombinant adenovirus serotype 5 (rAd5) vector-
based vaccine) have proven to effectively reduce viral load in Mamu-A 01 negative rhesus 
macaque-SIV challenged models of infection (Liu et al., 2009). The adenovirus, serotype 5 
(Ad5) vector developed by Merck and the NIH was first observed to induce high magnitude 
CD8+ responses and immune protection against SHIV89.6P in macaques (Shiver et al., 2002) 
and went on to form part of the STEP study. In another study, priming with recombinant Bacille 
Calmette-Guerin rBCG), the attenuated Mycobacterium bovis bacterium, containing SIV Gag, 
Pol and Env followed by a rAd5 boost expressing the same antigens successfully induced 
persistant cellular responses compared to animals that only received rAd5 vaccination alone 
(Cayabyab et al, 2009). Studies conducted at UCT, using Chacma baboons indicate that rBCG 
expressing Gag can be used to effectively prime immune responses after boosting with virus 
(Chapman et al., 2010).  
Vaccine studies in NHPs have re-affirmed that in order to achieve a sustained level of 
protection, an effective vaccine should stimulate T cells that generate HIV-1 specific, protective 
and long lived effector memory and central memory responses (Robinson, 2007). T cell memory 
is defined as long lived responses that can be initiated long after the initial exposure to antigen 
to induce a robust, strong secondary immune response to the same antigen upon re-encounter 
(Dutton et al., 1998).  In a study in which rhesus macaques were primed with plasmid DNA 
containing SIV antigens and boosted with rAd5 indicated the increased survival and reduced 
viral loads after SIV challenge is associated with the presence of CD4+ central memory T cells 
(Tcm) (Letvin et al., 2006). These results formed the basis of the ongoing phase 2b efficacy trial 
that investigate these vaccines in the HIV Trial Network (HVTN)-505 study.  
Central memory CD8+ T cells have also been found to play a key role in the control of viral 
replication following challenge in rhesus macaques vaccinated with DNA prime and either 
recombinant viral vector boost (Vaccari et al., 2005; Acierno et al., 2006). Hansen et al., (2011) 
demonstrated that viral control is associated with SIV specific CD8+ T cell responses in rhesus 
macaques vaccinated with cytomegalovirus vaccines and that CD8+ effector memory (Tem) 
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In addition, studies involving rhesus macaques that were passively immunised with broadly 
neutralising antibodies showed that the vaccinated animals were protected against infection 
from virulent SHIV challenge (Baba et al., 2000; Parren et al., 2001; Veazey et al., 2003; 
Ferrantelli et al., 2004.) These studies provide evidence that vaccination designed to elicit 
broadly neutralising antibodies to provide protection against infection is possible. 
 Non-human primates have been used to identify routes of immunisation that induce the best 
possible immune responses and protection. In a recent study, SIV DNA prime and SIV rMVA 
boost vaccines administered via rectal immunisations in rhesus macaques, were found to 
induce SIV specific cellular immune responses both systemically and mucosally. Intranasal 
immunisation with the same vaccines elicited better cellular and humoral responses compared 
to animals vaccinated via the intra-muscular route and protected against SIV vaginal challenge 
(Manrique et al., 2013). 
Studies in NHPs have also been useful in determining the ideal immunogens that should be 
incorporated into candidate HIV-1 vaccines. It has been sugg sted that low viral load and higher 
levels of CD4+ T cells can be achieved by increasing the breadth of immunogens (particularly to 
a broad range of Gag epitopes) recognised by the immune system (Rolland et al., 2008). In a 
study by Sun et al. (2010), it was found that a vaccine regime containing all genes of the 
SIVmac239 virus afforded a broader immune response in macaques compared to vaccination 
with only a single antigen. Candidate HIV-1 vaccines should be designed to present the immune 
system with a complement of relatively conserved and immunogenic viral epitopes such as Gag 
and Nef in order to initiate an early, rapid and effective response before the virus has produced 
escape mutants (Addo et al., 2003). It has been demonstrated that SIV Gag, Pol, and Env 
reduced SIV infection in macaques and Env in particular was required for protection against SIV 
(Barouch et al., 2012).  Gag-specific cellular immune responses have also been correlated with 
control of viral infection in vaccinated rhesus monkeys following SIV (Shiver et al., 2002; 
Iwamoto et al., 2010; Barouch et al., 2012; Hansen et al., 2011; Liu et al., 2009). In fact, it has 
been found that Gag-specific but not Pol- or Env-specific CD8+ responses were associated with 
viral inhibition (Stephenson et al., 2012). These studies highlight the need to incorporate Gag 
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1.3.2.3. Lessons from clinical trials 
 
During the last 26 years of research, a total of 220 HIV vaccine trials have been conducted but 
only some have advanced to phase 2b proof-of-concept or phase 3 clinical efficacy trials (as 
reviewed by Saunders et al., 2012). The approach of the vaccines tested in these trials was 
either to induce antibody responses, T cell responses or both. Despite the poor to moderate 
results observed, these trials have outlined the challenges and opportunities for the 
development of an effective HIV-1 vaccine. This review highlights the outcomes of four of these 
trials and how these findings enhanced the field of the HIV vaccine development.  
i. VAX003 and VAX004 
 
The first two vaccines tested in phase 3 clinical trials were comprised of the recombinant gp120 
proteins from Env and were administered with the adjuvant alum manufactured by Vaxgen. 
These vaccines aimed to induce Env-specific antibodies. The VAX003 was comprised of one 
clade B and one clade E gp120 (AIDSVAX B/E) and was used to vaccinate high risk drug users 
in Thailand. The participants received seven immunisations over 30 months. The VAX004 was 
comprised of two clade B gp120s (AIDSVAX B/B) and was tested in a cohort of high risk 
individuals from Canada, The United States of America and The Netherlands (Harro et al., 
2004; Pitisuttihum et al., 2006).  
These early antibody based candidate vaccines induced gp 120 specific antibody responses but 
overall the results were disappointing. The vaccines induced no protection from infection, and 
were not able to delay the progression of disease or reduce viral load in phase III human trials 
(Flynn et al., 2005; Pitisuttihum et al., 2006). It is believed that the immunogens used in these 
trials were not able to neutralise circulating strains of HIV-1 despite being able to neutralise 
laboratory strains of the virus (Mascola et al., 1996). However, these trials confirmed that B cell 
based vaccines require potent broadly neutralising antibodies. These trials also showed that 
candidate HIV vaccines aimed at eliciting humoral responses can be used safely in humans.   
ii.  STEP and Phambili study 
 
The STEP study was a phase IIb proof of concept trial which commenced in 2004 and 
evaluated the non-replicating MRK adenovirus type 5 (MRKAd5) vaccine that expressed gag, 
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responses to decrease viral load and prevent transmission. The STEP (HVTN 0052) study 
enrolled healthy, but at risk participants from the Americas, Caribbean and Australia whilst the 
Phambili trial (HVTN 0053) enrolled individuals from South Africa.  
During preclinical evaluation, vaccinated rhesus macaques showed effective control of viral load 
after challenge with SHIV (Shiver et al., 2002; Casimiro et al., 2005). The phase 1 clinical trial 
also deemed this vaccine safe and the Ad5 vector proved to be effective in terms of inducing 
detectable immune responses. However, the phase 2b clinical trial was terminated in 2007 
following a report from the Data and Safety monitoring Board that deemed the study incapable 
of determining the efficacy of the vaccines (Fauci et al., 2008). Despite the detection of HIV-1 
specific CD8+ T cell responses directed towards gag, pol and nef, there was no significant 
evidence of protection in vaccinated individuals compared to unvaccinated individuals that 
received placebos (Gray et al., 2010). Further analysis of the failure of the trial indicates that 
vaccine specific T cells responses exerted weak selection pressure on the viruses that 
eventually infected vaccinated participants (Rolland et al., 2011). 
Further analysis of this study indicated that the rate of HIV-1 infection was increased in 
participants, particularly in uncircumcised men, that were Ad5 seropositive and hence 
possessed pre-existing anti-vector immunity (Buchbinder et al., 2008; Gray et al., 2010). The 
increased risk of HIV acquisition among vaccinated Ad5 seropositive participants compared to 
individuals that received the placebo could be a result of higher levels of Ad5-specific CD4+ T 
cell responses in the seropositive individuals (Gray et al., 2010).  It is hypothesised that the 
rapid expansion of Ad5-specific CD4+ T cells after vaccination gives rise to potential target cells 
for infection. As reviewed by Barouch (2010), other rare serotypes of adenoviruses which have 
lower prevalence in human populations such as Ad26 and Ad35 (Vogels et al., 2003; Abbink et 
al., 2007) are being investigated as potential HIV-1 vaccine vectors in phase 1 clinical trials.   
From the STEP study, it is evident that pre-existing anti-vector immunity, particularly to Ad5, can 
negatively impact the success of vaccines. In addition, the use of Ad5 vaccine only and not the 
more potent prime-boost vaccination regimen induced responses with insufficient magnitude 
and breadth to induce protection from infection (McElrath et al., 2010). This trial also highlighted 
the importance of investigating the impact of mucosal tissue responses during the evaluation of 
HIV vaccines as vaccinated, but uncircumcised men appeared to be infected at higher rates 
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iii. RV 144 
 
The RV 144 study (Thai trial) conducted in Thailand investigated the efficacy of canarypox 
ALVAC prime expressing gag, pol and env followed by AIDSVAX CM-244 Env rgp120 protein 
boost was the first heterozygous prime-boost vaccine regimen in phase 3 clinical trials. In 
contrast to the other clinical trials discussed, the vaccines tested could induce both T cell and 
humoral immune responses. Infection was reduced in 31.2% of individuals in the vaccinated 
arm of the study compared to the placebo arm (Rerks-Ngram et al., 2009).   
However, this efficacy was insufficient for licensure, but further analysis of the trial revealed 
several key factors that will contribute to the development of future HIV-1 vaccines. This study 
was the first to demonstrate modest, but promising vaccination efficacy although no differences 
in viral load was observed in vaccine and unvaccinated participants. This vaccine regimen was 
found to induce strong Env-specific antibody responses which decreased in magnitude after the 
first year (McElrath, 2010).  
In addition, Env-specific CD4+ T cell proliferative responses were observed in vaccinated 
individuals and there were no significant HIV-specific CD8+ T cell responses in vaccinated 
individuals (McElrath and Haynes, 2010; Rerks-Ngram et al., 2009 ). This trial demonstrated 
that although no neutralising antibodies were present, V1/V2 binding antibodies in vaccinated 
individuals were associated with protection (Haynes et al., 2012; Zolla-Pazner et al., 2013) and  
Env specific IgA antibodies were associated with infection and identified as a correlate of risk 
(Haynes et al., 2012).  
A novel  set of immunogens are being investigated for incorporation in next generation vaccines 
which induce non-neutralising, broadly neutralising antibodies, the possible induction of ADCC, 
ADCVI responses together with improved T cell responses (O’Connell et al., 2012; Bianchi et 
al., 2010 Koup et al., 2011).  
1.3.3. Delivery vector systems for HIV-1 vaccines used in the current study 
 
In the past, live attenuated SIV vaccines have proven to be effective in rhesus monkey (Daniel 
et al., 1992) but the safety concerns of using live HIV in humans are too great.  As such, novel 
vaccine strategies based on vector systems have been developed over the past decade. These 
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in plasmid DNA vector vaccines and recombinant viral vector vaccines. This review will highlight 
the vectors used as part of this study conducted at UCT.  
1.3.3.1. MVA  
 
The Modified vaccinia Ankara (MVA) is an Orthopoxvirus that has been attenuated by 
approximately 570 passages in primary chicken embryo cells and is replication defective in 
mammalian cells making it safe for use in humans (reviewed by Sutter and Staib, 2003). Like 
other pox-viruses, the genome of MVA is large enough to accommodate immunogens making it 
an effective gene delivery vector (Blanchard et al., 1998).  The production of MVA based 
vaccines is cost effective, and as vector, MVA is usually stable after freeze drying (Gomez et al., 
2008). In addition, MVA vectors are able to induce immune responses despite lacking 
replication mechanisms (Blanchard et al., 1998).   
MVA vectors containing SIV or HIV antigens as part of heterologous prime-boost strategies 
have been able to successfully elicit both antibody and cytotoxic T cell responses in rhesus 
macaques and effectively controlled SHIV 89.6P and SIVmac251 mucosal challenge 
(Ramsburg et al., 2004; Horton et al., 2002; Amara et al., 2001). Evidence in studies conducted 
using rhesus macaques suggests that MVA based vaccines administered via the nasal mucosal 
route is associated with increased survival after challenge and stronger immunogenicity 
(Ourmanov et al., 2009; Manrique et al., 2011). There have also been reports of long-lived, 
CD8+ immune responses induced by MVA based vaccination in macaques (Nigam et al., 2007).  
In the context of HIV vaccine development, the MVA based vaccines have proven to be safe yet 
highly immunogenic in both preclinical and phase 1 clinical trials (Mwau et al., 2004; Cebere et 
al., 2006; Harari et al., 2008). Several clinical trials in healthy and HIV-1-infected human 
participants have been conducted using MVA-based vaccines (Goepfert et al., 2011; Keefer et 
al., 2011; Vasan et al., 2010). These studies indicate that recombinant MVA vectors are safe 
and are able to induce HIV-1-specific immune responses when used in combination as part of a 
heterozygous, prime-boost vaccine strategy. 
Safety, moderate antibody and T cell responses were detected in the phase 2 clinical trial 
performed by IAVI in which participants were vaccinated with DNA prime and MVA boost with 
both vectors containing HIV clade A immunogens (Paris et al., 2010; Cebere et al., 2006; Hanke 
et al., 2007).  In a recent phase 1 clinical trial conducted in uninfected volunteers that received 
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MVA boost encoding the same genes and RT (TB-M4). The results of this study indicate that 
the vaccines were safe and Tier 1 neutralising antibodies were detected against viruses 
(Mehendale et al., 2013). Investigation of vaccine specific cytokine production revealed that T 
cell responses were polyfunctional and Env specific responses were predominantly skewed 
towards the CD4+ phenotype (Hayes et al., 2013).  
1.3.3.4. DNA plasmids 
 
Plasmid DNA vector delivery systems generate HIV proteins within the host, and allow for direct 
transfer of genes since this vector does not rely on pathogenic delivery of immunogens (Brave 
et al., 2007).  DNA plasmids are easy to manipulate and are often modified with specific 
promoters and RNA stabilisers. In addition, a variety of possible codon optimised HIV genes can 
be incorporated into the plasmid and are relatively cheap to produce, stable and safe (as 
reviewed by Hanke, 2001). The plasmid DNA is presented to host cells by antigen presenting 
cells and begins transcription and translation of mRNA into immunogenic proteins which are 
released into the cytoplasm. The antigenic proteins are then presented by major 
histocompatability complex class I (MHC I) molecules to CD8+ T cells.  
Pre-clinical evaluation of DNA plasmid based HIV vaccines have been shown to elicit HIV 
specific responses in mouse models (Giri et al., 2004) and to confer protection against 
SHIV89.6P in macaques (Barouch et al., 2000). These immune responses can be enhanced in 
vaccine regimens consisting of DNA plasmid vectors in conjunction with other vectors in a prime 
boost vaccination strategy.  
Recent phase I clinical studies have shown that heterozyogous vaccination regimens 
comprising of one or more DNA primes followed by boosting with either Ad5 (Jaoko et al., 2010) 
or rMVA (Goepfert et al., 2011) are well tolerated in seronegative participants. Furthermore, 
these studies suggest that the highest frequency and magnitude of T cell immune responses 
were detected in the individuals that received DNA priming compared to those without. These, 
and other ongoing clinical trials, including the HVTN 505 (HVTN website) have been initiated in 
the hope that DNA plasmids containing HIV antigens present in the boost vaccine induce a 
more effective and rapid cell mediated response upon infection.  Several DNA plasmid based 
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1.3.3.5. Virus-like particles  
 
HIV-1 virus like particles (VLPs) are a class of subunit proteins which have the same structure 
of the surface envelope found in HIV-1 virions but do not contain genetic material from the virus 
(Jennings and Bachmann, 2008). Therefore the VLPs are not infectious and non-replicating and 
can be used safely. Most VLPs are produced by expressing structural proteins which self 
assemble once inside the cell. It is possible that VLPs can be used in combination with other 
vaccines as part of prime boost regimens to induce both humoral and cell mediated responses 
against HIV-1 (Scotti and Rybicki, 2013). 
Compared to vaccination with soluble Env protein, VLPs containing the Env of HIV-1 have 
shown to induce broader cellular and humoral immunity (McBurney and Ross, 2009). To date, 
there is evidence that VLPs designed to induce anti-CCR5 immune response to prevent HIV 
binding and entry have been able to successfully induce strong anti-CCR5 IgG and IgA 
responses in both serum and mucosal compartments in the rat model (Hunter et al., 2009).   
The advantages of using VLPs to induce HIV-1 specific immune responses are reviewed in 
Doan et al., 2005. In summary, these particles are safe, can induce strong immune responses 
specific to HIV-1 epitopes and are required in smaller doses compared to other vaccines without 
compromising immune responses. Vaccination with p55gag VLPs in rhesus macaques induced 
long-lived, broad CD8+ cytotoxic responses and have thus been considered useful as part of a 
prime-boost regimen (Paliard et al., 2000). Used in combination to boost DNA plasmid 
vaccination containing HIV-1 subtype C gag (pTHGag) and recombinant pantothenate 
auxotroph of BCG (rBCGpan-Gag),  VLPs containing the matched gene (Pr55gag) have been 
able to induce broad, polyfunctional responses in vaccinated Chacma baboons (Chege et al., 
2008b; Chege et al., 2013).  
1.4 HIV vaccine development efforts at UCT 
 
For over a decade, the University Of Cape Town (UCT) HIV Vaccine Development Group has 
been engaged in the development of HIV-1 subtype C vaccine in South Africa. To date, 
candidate vaccines based on vectors such as BCG, poxviruses and include DNA and subunit 
vaccines have been developed and tested in various prime-boost combinations in mice and 
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optimisation of novel vaccines, the group has also documented the utility of the Chacma baboon 
as a model for HIV-1 vaccine evaluation (Chege et al., 2005; Burgers et al, 2009).   
The group has already reported that prime-boost immunization of Chacma baboons with rBCG 
and Pr55Gag virus-like particle (VLP) based on HIV type 1 (HIV-1) subtype C induces Gag 
specific responses (Chege et al., 2009). The Pr55gag virus-like particle (VLP) was previously 
shown to boost the immune response when mice are primed with a subtype C gag DNA 
vaccination (Jaffray et al., 2004) and was subsequently used together with other candidate 
vaccines in heterozygous vaccination regimens in NHPs.  
One of the promising vaccine candidates developed by the group is the SAAVI MVA-C 
comprised of a polyprotien including gag, reverse transcriptase, tat and nef (grttn) and truncated 
pg150 (env) (Burgers et al., 2008) has also been used to prime Chacma baboons prior to VLP 
boost. In this case, Gag specific IFN-γ ELISPOT cellular immune responses and moderate 
humoral responses were induced in vaccinated animals (Chege et al., 2008a). In another group 
of baboons, vaccinated with a prime-boost regimen of pTHgag DNA- Pr55GagVLP vaccine, 
both humoral and cellular responses were observed using ELISA and IFN- ELISPOT assays 
(Chege et al., 2008b). In this case, the pTHgag DNA vaccine construct expressed the HIV-1 
subtype C gag gene of Du422 (van Harmelen et al., 2003; Williamson et al., 2003).  
To date, candidate vaccine developed by the group have been shown to induce successful 
cellular and moderate humoral responses in preclinical evaluation. In 2009, two HIV-1 vaccine 
candidates namely SAAVI DNA -C2 and SAAVI MVA-C have recently entered human clinical 
trials after being characterised in terms of potency and immunogenicity in both mice and NHP 
studies (Burgers et al., 2008; Burgers et al., 2009). 
 The ongoing trial (HVTN 073/SAAVI 102) aims to evaluate the safety and immunogenicity of 
SAAVI DNA-C2 vaccine boosted by SAAVI MVA-C vaccine in healthy volunteers in South Africa 
and USA. Immunogenecity testing revealed that the vaccines were safe and HIV-1 specific 
CD4+ and moderate HIV-specific CD8+ T-cell responses were detected (Williamson et al., 
2012). In addition, another phase 1 trial known as HVTN 086/SAAVI 103 has also been initiated 
to evaluate the safety of SAAVI DNA-C2, SAAVI MVA-CC and Norvartis subtype C gp140 with 
MF59 adjuvant (Williamson et al., 2012).  Due to this success, the efforts of the UCT HIV 
Vaccine Development Group to develop novel vaccine candidates and to improve on existing 
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2. PROBLEM IDENTIFICATION AND RATIONALE 
 
The UCT HIV vaccine development group has already reported that immunisation with a 
recombinant modified vaccinia Ankara (MVA-C) prime and Pr55 Gag VLP boost based on HIV-1 
subtype C has successfully induce Gag-specific responses in Chacma baboons (Chege et al., 
2008a) by IFN-γ ELISPOT assay measurements. In addition, both humoral and cellular 
responses (based on ELISA and IFN-γ ELISPOT assay respectively) have been observed in 
another group of baboons, primed with pTHgag DNA and boosted with Pr55 Gag VLPs (Chege 
et al., 2008b). However, as discussed earlier, the evaluation and characterization of T cell 
immune responses induced by candidate vaccines cannot be limited to IFN-γ ELISPOT data. 
There is now a need to develop additional assays to further investigate immunological 
characteristics of these vaccines such as the development of durable vaccine specific memory 
T cells. To date, the baboon model has been used to evaluate candidate vaccines which are 
designed to generate neutralizing antibodies (Anderson et al., 1989; Stephens et al., 1992; 
Haigwood et al, 1992), but only a limited number of studies have investigated the 
immunogenicity of vaccines that induce cellular immune responses (Chege et al., 2008a; Chege 
et al., 2008b; Burgers et al., 2009).  
Therefore, there is now a need to further characterise the quality of the vaccine induced T cell 
immune responses by assessing the Gag-specific cytokine production and memory recall 
responses generated by the SAAVI MVA-C/VLP and DNA/VLP prime-boost vaccination regimen 
in Chacma baboons by flow cytometry. This will involve the development of flow cytometry 
panels made up of T-cell memory markers and functional markers to determine the level of 
cytokine production and the distribution of vaccine specific memory T cell responses induced by 
these candidate vaccines. However, there is a need to identify cellular markers of T cell memory 
that have previously been used in human and rhesus macaque studies that can be used to 
delineate T cell memory populations in the Chacma baboon model. Furthermore, the selected 
markers need to be further assessed and characterised based on additional functional and 
phenotypic parameters to ensure that these markers accurately define memory populations in 
the Chacma baboon. These new multi-parameter flow cytometry panels could be used to 
evaluate future candidate HIV vaccines in preclinical development using the Chacma baboon as 
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3. AIM AND OBJECTIVES 
 
The aim of the current study was to characterise the T cell memory phenotype distribution in 
peripheral mononuclear cells (PBMCs) isolated from Chacma baboons vaccinated with SAAVI 
MVA-C/VLP and DNA/VLP prime-boost vaccination regimens by flow cytometry. 
 
The following specific objectives were used to achieve the aim of this study: 
 
i.  Identify and evaluate various anti-human antibodies to select a suitable combination of 
markers to detect T cell memory subsets in baboon PBMCs. 
  
ii. To determine the suitability of the selected markers by investigating the functional, 
activation and maturation characteristics of the baboon T cell memory phenotypes 
defined by these markers using a four-colour flow cytometry. 
 
iii. Investigate the vaccine specific T cell memory phenotype distribution in Chacma 
baboons vaccinated with SAAVI MVA-C/VLP and DNA/VLP prime/boost vaccine 
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2.1. General laboratory equipment 
 
Samples were thawed, stimulated and stained in the Primate Immunology Laboratory 
situated within the Division of Medical Virology, UCT. All experimental procedures and 
preparation of media and wash buffers were performed in a Bio-safety level II (BSL II) 
laminar flow. Cryopreserved material was stored in access restricted freezer rooms. Flow 
cytometry analysis was conducted using the FACS Calibur situated within the Division of 
Virology, UCT or the BD LSRII Fortessa situated within the Institute of Infectious Diseases 
and Molecular Medicine (IIDMM).  
2.2. Thawing of cyropreserved PBMCs 
 
Cryopreserved peripheral blood mononuclear cells (PBMCs) samples from Chacma 
baboons (Papio ursinus) were used in this study. All animals were part of previous studies 
aimed at investigating immune responses to candidate HIV-1 vaccines developed at the HIV 
vaccine discovery group, UCT. PBMCs were cryopreserved at 1x107 to 2x107 cells per ml in 
storage media containing foetal bovine serum (FBS, Gibco Invitrogen) containing 10% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and stored in a vapour phase liquid nitrogen 
cryotank. 
During the thawing procedure, cryopreserved PBMCs were removed from liquid nitrogen, 
and thawed in a water bath set at 37ºC for approximately 3 to 5 minutes. Care was taken not 
to disrupt the tubes during the thawing process so as to prevent cell damage by ice micro-
crystals formed between cells and to maintain maximum cell viability.  Thawed PBMCs were 
then quickly transferred into 50ml centrifuge tubes. To remove the freezing media which 
contained DMSO, 25ml of freshly prepared Roswell Park Memorial Institute (RPMI) 1640 
media (Gibco, Invitrogen) containing 0.01% Penicillin and Streptomycin (PenStrep) 
(Invitrogen) and further supplemented with 1% FBS (R1) was warmed to room temperature 
and then added drop wise to protect the cells from osmotic and heat shock.  The cells were 
centrifuged at room temperature at relative centrifugal force (RCF) of 230xg (1200rpm) for 
10 minutes. The supernatant was discarded and the remaining cell pellet was re-suspended 
in 5ml of R1 containing DNAse (Roche) at a final concentration of 0.02mg/ml and incubated 
at room temperature for 2 to 5 minutes. The cells were treated with DNAse to hydrolyse the 
DNA extruded from lysed cells in order to prevent cell clumping. The DNAse was then 
removed from the cell suspension by washing the cells with 25ml of R1 as above , the cell 
pellet was re-suspended in pre-warmed RPMI 1640 media supplemented with 20% FBS 













The cells were rested to reduce the detection of non-specific responses or background 
responses during flow cytometry analysis (Horton et al., 2007). The common reagents used 
during the thawing process are summarised in Table 2.1. 
Table 2.1. Description of reagents used for thawing and culture of baboon PBMCs 
Reagent Description Source 




Penicillin Streptomycin Antibiotic  containing 5000 units/ml Penicillin and 
5000 µg/ml Streptomycin to prevent contamination 
in cell culture 
 
Invitrogen 
FBS Heat-Inactivated foetal bovine serum to 
supplement cell culture media 
 
Invitrogen 
R1 RPMI supplemented with 1% FBS 
 
* 
R10 RPMI supplemented with 10% FBS 
 
* 
R20 RPMI supplemented with 20% FBS 
 
* 




* Prepared in Primate Immunology Laboratory (UCT) 
2.3. Viable cell counting 
 
The number of viable cells recovered and the viability (calculated as a percentage) of each 
sample was determined after the cells were rested for 4-6 hours. The Trypan blue exclusion 
test was used. This test is based on the principle that viable cells with intact cell membranes 
will not allow Trypan blue dye to enter the cytoplasm and therefore live cells will not stain 
blue. In contrast, dead cells that do not have intact cell membranes will take up the dye and 
stain blue (Strober, 2001). Since red blood cells, like viable cells, will not take up the Trypan 
blue dye, contaminating red blood cells in the sample could be mistaken for live lymphocytes 
during counting. To minimise this error, Turk’s solution was used in parallel with the Trypan 
Blue. Turks solution contains acetic acid to lyse red blood cells and stains the nuclei which is 
absent in mature red blood cells. However, Turk’s solution does not differentiate between 
live and dead cells and thus indicates the total number of cells. In summary, the cells in 
suspension were stained in a 1:1 ratio with either Turk’s solution or Trypan Blue. The 
number of dead cells (determined by Trypan Blue exclusion test) were excluded from the 
total number of cells (determined by Turk’s solution staining), to calculate the number of 













Neubauer haemocytometer cell counting chamber (Hausser Scientific) and light microscopy. 
The number of viable cells was then adjusted to 10-20x106 per ml by adding the appropriate 
volume of media.  
2.4 Stimulation of PBMCs for the detection of functional and activation 
markers 
 
For assays intended to detect the production of cytokines by intracellular staining (ICS), the 
cells were stimulated with Gag peptide pools or a polyclonal T cell stimulant such as the 
Staphylococcal enterotoxin B (SEB) (Sigma-Aldrich) as a positive control. In addition, cells to 
which no stimulant was added were used as negative (unstimulated) controls and were used 
to determine the level of background or non-specific responses for each experiment. The 
reagents used for stimulation are described in Table 2.2. 
 In general, the cells in suspension were transferred into V-bottomed 96 well plates and 
stimulated with SEB at a final concentration of 2µg/ml or Gag subtype C peptide pools 
(prepared in-house) at a final concentration of 2µg/ml at 37°C for a total of 16 hours in a 
humidified atmosphere of 5% CO2.  For the detection of vaccine specific cytokine production 
by T cells, co-stimulants anti-CD28 and –CD49d antibodies were also added at the final 
concentrations of 1µg/ml each to maximise antigen presentation to T cells via T cell 
receptors (TCRs). This induces T cell activation required for the in vitro production of 
cytokines (Waldrop et al., 1998). The CD28 molecule, as reviewed in Lenschow et al., 
(1996), binds to the CD80 and CD86 receptor expressed on antigen presenting cells and 
provides a second cross-linked co-stimulatory signal required for T cell activation. CD49d, an 
α4β1 integrin, which is involved in the CD3-dependent CD4+ T lymphocyte activation, 
provides further co-stimulatory signals to induce the production of IL-2, TNF-α and IFN-γ 
(Udagawa et al., 1996). 
For the detection of cytokine production by ICS, Brefeldin A (BFA) (Sigma-Aldrich), an 
antibiotic produced by Penicillium brefeldianum fungus, was added to the cells at a final 
concentration of 10µg/ml after the first 2 hours of stimulation.  BFA causes the accumulation 
of cytokines produced within the cell by blocking the transport of cytokines from the 
endoplasmic reticulum (ER) to the Golgi complex (Klausner et al., 1992; Nylander and 
Kalies, 1999). In this way, the cytokines remain within the cell and can be detected by 
intracellular staining (ICS).  For the detection of the activation marker CD69, BD GolgiStop 
(BD Biosciences), a protein transport inhibitor containing monensin was used instead of 
BFA. The use of BFA has been reported to block CD69 expression in a large proportion of 













Streptomyces cinnamonensis, used as a substitute for BFA and prevents the transport of 
proteins and cytokines out of the Golgi complex (Jung et al., 1993).  The cytokines or protein 
markers produced then accumulate within the cell and can be detected by ICS. After the 
addition of either BFA or monensin, the cells were incubated for the remainder of the 16 
hours after which, they were removed from the incubator and placed at 4°C to stop the 
stimulation and stored  for no longer than 6 hours or until staining.   
 
Table 2.2. Description of reagents used to stimulate baboon PBMCs. 
Reagent Description Source 




Gag-C peptide pools Peptide pools comprising of 66 synthetic peptides 
which span the HIV-1 subtype C Gag protein 
sequence. These peptides were 15–18 amino acids in 
length and overlapped by 10 amino acids. The 
peptides were dissolved in 100% DMSO (Sigma) and 
have been previously described in Masemola et al., 





anti-CD28 Co-stimulatory molecule used to augment T cell 
receptor (TCR) signalling 
Merck 




BFA Brefeldin A from Penicillium brefeldianum to inhibit 
protein transport between ER and the Golgi complex 
and allows for the accumulation of newly synthesised 





Isolated from Streptomyces cinnamonensis. Prevents 
transport of newly synthesised proteins in the Golgi 
complex and allows for the accumulation of newly 
synthesised proteins within the cell 
BD Bioscience 
 
2.5. Antibodies and fluorochrome conjugates 
 
Fluorochromes typically used for flow cytometry are fluorescent dyes that absorb light 
energy at low wavelengths (referred to as excitation) and re-emit this light energy at longer 
wavelengths within the visible spectrum (referred to as emission). Monoclonal antibodies are 
directly conjugated to fluorochromes that have distinct excitation and emission ranges. It is 
possible to detect these antibodies bound to a cellular marker of interest from cells by 













fluorochrome then is channelled through a series of filters and mirrors to detectors assigned 
to specific wavelengths. The light signals are then converted to electronic data which can be 
depicted graphically.  In this study, antibodies were conjugated to fluorochromes classified 
either as classic dyes, tandem dyes or inorganic Quantum Dot (Qdots) nanocrystals.  
 Classic dyes are stable, naturally occurring fluorescent molecules such as fluorescein 
isothyocyanate (FITC); phycoerythrin (PE); peridinin chlorophyll protein (PerCP) 
allophycocyanin (APC); Alexa Fluor (from Molecular Probes) and Pacific blue (based on the 
6,8-difluoro-7-hydroxycoumarin flourochrome). On the other hand, tandem dyes are less 
stable compared to the classic dyes and are light and temperature sensitive. However, 
tandem dyes offer a wider range of emission which increases the number of possible 
parameters (markers) that can be detected by a single laser (adapted from AbD Serotec 
website). Tandem dyes are usually made up of two covalently linked fluorescent dyes and 
emits fluorescence by the process of fluorescence resonance energy transfer (FRET). One 
of the dyes, usually a classic dye, is excited by the laser and the energy it emits is 
transferred to the second dye such as cyanine dye (Cy) 5, Cy5.5 or Cy7, which acts as an 
acceptor molecule and then produces a combined fluorescence emission. The Qdot 
semiconductor nanoparticles however, are made up of a cadmium selenide core coated with 
zinc sulfide and the wavelength of emitted light can be varied according to the size of the 
core (Chattopadhyay et al., 2006). In addition, these nanocrystals are photostable and have 
narrow emission spectrum which reduces the spectral overlap between dyes.  
The antibodies used in this study were directly conjugated to fluorochromes FITC, PE, 
PerCP, phycoerythrin-cyanine 5 (PECy5), phycoerythrin-cyanine 5.5 (PECy5.5), APC, 
allophycocyanin-cyanine 7 (APC.Cy7) and Pacific Blue flourochromes. Some antibodies 
were conjugated to Quantum Dot Nanocrystals (Invitrogen) namely Qdot605. Table 2.3 



















Table 2.3 Properties of flurochromes used in this study for flow cytometry analysis by 
the FACS Calibur and/or LSR II Fortessa.  
Fluorochrome Type of dye Excitation max (nm) Emmision max (nm) 
APC* Classic 650 660  
FITC* Classic 494 520 
PE* Classic 496 578 
PerCP* Classic 482 678 
PECy5* Tandem 496 667 
PECy5.5. Tandem 488 690 
APCCy7 Tandem 650 785 
Pacific Blue Classic 401 452 
Qdot 605 Qdot nanocrystal 350 605 
*Used for flow cytometry analysis by FACS Calibur and LSR II Fortessa. Adapted from AbD Serotec 
website, http://static.abdserotec.com. 
 
Several commercially available clones of anti-human monoclonal antibodies are known to 
detect CD3, CD4, CD8, CD28, CD95, CD27, CD45RA, CD69, IL-2, IFN-γ, TNF-α, CCR7 and 
CCR5, in PBMCs isolated from humans and/or rhesus macaques.  Certain clones of anti-
human CD3, CD4, CD8, IFN-γ and IL-2 antibodies have also previously been used to stain 
baboon PBMCs (Casimiro et al., 2003; Chege et al., 2005; Chege et al., 2008b; Burgers et 
al., 2009). In the current study, several clones of homing and maturation markers such as 
CD45RA, CD27, CD28, CD95, CCR5 and CCR7 were tested for cross-reactivity using 
baboon PBMCs. Table 2.4 provide  a comprehensive list of antibodies and their conjugates 













Table 2.4.  Properties of antibody-fluorochrome conjugates used in this study.  
Antibody Clone Fluorochrome Manufacturer Function/role of marker * 
CD3 SP34-2 PerCP BD Phenotypic surface marker of T cells and can be expressed on NK-like T cells 
FN-18 FITC Invitrogen 
SP34-2 APC.Cy7 BD 
CD4 
 
L200 PerCP BD Phenotypic surface of helper T cells and can be expressed on 
monocytes, macrophages and dendritic cells. Acts as a co-receptor for MHC Class II 
peptides. 
L200 APC BD 
S5 PE.Cy5.5 Invitrogen 
CD8 
 
SK1 PerCP BD Phenotypic surface marker of cytotoxic T cells 
SK1 APC BD 
3B5 QDot605 Invitrogen 
CD28 CD28.2 PE BD Co-stimulatory molecule involved in TCR induced t cell activation. 
Memory marker for T cells capable of secreting IL-2 (eg. naive T cells and Tcm)  CD28.2 APC BD 
CD28.2 FITC BD 
CD95 DX2 PECy5 BD Memory marker to detect Fas expression on T cells (eg. Tem) 
DX2 FITC BD 
DX2 APC BD 
CD45Ra 5H9 PE BD Isoform of CD 4 which is a marker of naive T cells 
5H9 PECy5 BD 
CD27 M-T271 PE BD Co-stimulatory molecule involved in TCR induced T cell activation. 
Memory marker for T cells capable of secreting IL-2 (naive T cells and Tcm)  M-T271 APC BD 
 M-T271 FITC BD 
CD69 FN50 PE BD Early marker of T cell activation. 
TNF-α mAB11 PE BD Th1 cytokine 
IL-2 MQ1-17H12 PE BD Th1 cytokine 
IFN-γ 4SB3 PE BD Th1 cytokine 
CCR5 3A9 PE BD Regulates lymphocyte chemotaxis and activation. Co-receptor for HIV-1 infection. 
CCR7 150503 PerCP R&D systems Involved in the recruitment and retention of cells to lymphoid tissues 













2.6. Principles of flow cytometry 
 
Flow cytometry allows for the measurement and analysis of the characteristics of a single 
particle (0.2 to 150μm in size) as it passes through a beam of light from a laser source. 
Usually, flow cytometry is used to characterise cells by assessing the relative size, 
granularity and fluorescence of cells that have been stained with appropriate fluorescent 
molecules (flourochromes) conjugated to antibody markers of specific surface or intracellular 
epitopes. The components of a flow cytometer include (i) a fluidics system which conveys 
the particles (cells) in a single stream to be interrogated by a laser beam; (ii) an optics and 
detection system comprising a number of laser at different wavelengths that can illuminate 
the particle, as well as optic filters and mirrors to direct the light emitted from the particle to 
the appropriate detectors and (iii) a signal processing component that converts light signals 
generated into electronic data (Figure 2.1).   
 
Figure 2.1. Schematic overview of a typical two laser flow cytometer (eg. FACS Calibur). The 
fluidics system draws sample into a stream of single cells/particles by hydrodynamic focusing. The 
single particles can then be interrogated by the red laser (635nm) and blue laser (488nm) in this case. 
Light in the form of side scatter (SSC) or fluorescence is emitted to photomultiplier tubes (PMTs) and 
forward scatter (FSC) is emitted to a photodiode detector. A series of filters and mirrors direct the light 
to specific PMTs. The light signal is then amplified and converted into digital signals to be processed 













The light signals are channelled to a detector designated to a specific fluorescent dye by 
placing a filter and/or mirror in front of the photomultiplier tube (PMT), which allows only a 
narrow range of wavelengths to reach the detector. The filters used (Figure 2.2.) are either 
bandpass (BP) filters which allow the entry of light emission between a narrow range of 
wavelengths (eg. 500/50 BP will allow light in the range of 460 to 540nm to pass through to 
the PMT). Long pass (LP) filters allow light of longer or equal wavelength to pass through or 
short pass (SP) filters which allow light of shorter or equal wavelength to pass thorough to 
the PMT. Other components of this system include beam splitters such as dichroic mirrors 
that direct light of different wavelengths in different directions. For example, a 560 SP 
dichroic mirror transmits wavelengths of light 560 nm or shorter and reflects light at longer 
wavelengths at 45°. 
 
 
Figure 2.2. Light passage through typical longpass, shortpass and bandpass filters. These 
filters are placed in front of PMT d tectors in a flow cytometer (Taken from BD Bioscience website) 
iii. Signal processing 
On receiving a light emission signal from the cell (or particle), the detector allocates each 
signal into a voltage pulse. The voltage pulse signal is amplified by a voltage that is assigned 
to each PMT by increasing the current or by increasing the amplification gain settings. The 
amplifier settings can be set at logarithmic or linear amplification which are used to separate 
negative from dim positive signals and to amplify fluorescent parameters respectively. The 
voltage pulse is then converted into a digital signal by an Analogue-to-Digital Converter 
(ADC). The digital signal is assigned a specific number on a channel and data can be stored 
in this format. During data analysis, software programs graphically represent these data in a 















2.7. BD FACS Calibur and LSRII Fortessa 
 
In this study, the BD FACS Calibur (Figure 2.1) was used to screen for cross-reactive 
antibody clones, determine optimal antibody staining conditions and optimal staining 
concentrations. In addition, the FACS Calibur, containing two lasers (488nm and 635nm), 
was also used to select and validate cellular markers to be included in memory, and function 
flow cytometry panels to analyse baboon PBMCs. The configuration of the optical and 
collection system of the FACS Calibur used in this study is detailed in Table 2.5.  This study 
also made use of the BD LSR Fortessa which was used to investigate the memory and 
function phenotypes of vaccinated baboons. The machine used for this study had four lasers 
namely the blue (488nm), green (532nm), red (640nm) and the violet (407 nm) lasers, 
allowing for the detection of up to eighteen parameters simultaneously. The configuration 
and optical setup of the Fortessa used in this study is detailed in Table 2.6. 
Table 2.5. Configuration of four colour BD FACS Calibur 
Laser Detector Fluorochromes Filter 








670nm  LP 
Red (635nm) FL-4 (650nm) APC 661/16nm 
 
One of the most significant differences between these two machines is that the Fortessa 
could accommodate a larger number of markers and therefore more parameters of a call 
could be investigated simultaneously. Conversely, the FACS Calibur was limited to the 
detection of four colours but was readily available for use.  In addition, the limited 
parameters available in the FACS Calibur meant there were fewer problems caused by 
spectral overlap and thus limited the error introduced by compensation. However, it became 
necessary to evaluated more than four fluorochrome bound markers at a time in order to 
achieve the objectives of this study. The Fortessa allows for the simultaneous detection of 
markers of T cell lineage, viability, memory and cytokine production in one panel thus 
preserving reagents and irreplaceable samples from preclinical vaccine studies. The issue of 
spectral overlap and compensation was dealt with during the panel design by purposely 
assigning markers to flurochromes which have previously been found to exhibit minimum to 
zero spectral overlap with each other.  The use of compensation beads (described later in 













Both these flow cytometers share a common fluidics system and function to 
hydrodynamically focus the sample into a stream of single cells. The optics of the BD FACS 
Calibur include  a SSC detectors with a 488nm band pass filter for clear signal detection and 
red-diode laser (635nm) signal rejection.  A maximum of four fluorescence detectors and 
filters with band pass filters of 530 nm (FITC), 585 nm (PE), and >670 nm (PerCP or PECy5) 
and 661 nm (APC) can be used.  
 
In contrast to the FACS Calibur, the BD Fortessa collection system is composed of a series 
of PMTs arranged in octagon (green laser and violet laser detectors) or trigon (red laser and 
blue laser detectors). The octagonal arrangement of PMTs (Figure 2.3) ensures that light 
emission which enters the system are methodological reflected between detectors by a 
dichroic mirror or transmitted through the band pass filters to be detected by a specific PMT 
















Figure 2.3. Graphical representation of the octagonal arrangement collection system (specific 
to the green laser in the BD Fortessa). Each octagon is composed of a series of photomultiplier 
tubes (PMT) (A-H) and optics. Dichroic long pass (LP) mirrors and band pass (BP) filters are placed in 
front of the PMTs. Light  emitted from cell/particle enters the detector and engages with the LP 
dichroic mirror in front of the PMT labelled A first. If the wavelength of the light is in the range of 710 
to 840nm, it will pass through the LP filter and the BP filters (780/60) and be detected at the PMT 
labelled A.  If the wavelength of the light is shorter than 750nm, it is reflected by the dichroic mirror to 






















Blue 488nm SSC Side scatter (SSC)   488/10 
Blue 488nm (50mW) B710 PerCP Cy5.5 670LP 685/35 
Blue 488nm B515 FITC 505LP 515/20 
Green 532nm (150mW) G780 PECy7 750LP 780/60 
Green 532nm G710 PECy5.5 685LP 710/50 
Green 532nm G660 PECy5 635LP 670/30 
Green 532nm G610 Texas Red PE 600LP 610/20 
Green 532nm G560 PE EMPTY 585/15 
Green 532nm Empty N/A     
Green 532nm Empty N/A     
Green 532nm Empty N/A     
Red 640nm (40mW) R 780 APCCy7 740LP 780/60 
Red 640nm R 710 Alexa680, Alexa700 685LP 730/45 
Red 640nm R 660 APC, Alexa 647 EMPTY 670/30 
Violet 407nm (100mW) V800 QDot800 750LP 780/60 
Violet 407nm V705 QDot705 685LP 705/70 
Violet 407nm V655 QDot655 630LP 670/30 
Violet 407nm V605 QDot605, 585 595LP 605/40 
Violet 407nm V585 QDot565 556LP 585/42 
Violet 407nm V545 QDot545 535LP 560/40 
Violet 407nm V525 QDot525, Horizon V500 505LP 525/50 
Violet 407nm V450 Pacific Blue, ViViD EMPTY 450/50 
 
2.8. Selection of fluorochromes for multi-parameter flow cytometry 
panels 
 
The allocation of antibody markers of memory and function (cytokine production) to 
conjugates for four-colour analysis was determined by considering the following aspects of 
flow cytometry: 
i. Instrument configuration 
The ability of the cytometer to excite and detect a specific fluorochrome influences the 
antigen expression levels (brightness) and spectral overlap of the fluorochrome (Maecker et 
al., 2004). Therefore, in order to determine which fluorochrome conjugates to use, the 
















ii. Antigen expression levels (Brightness) 
The brightness of a fluorochrome conjugate is usually a measure of the cell-associated 
fluorescence intensity when it binds to its cellular antigen (Baumgarth and Roederer, 2000). 
Commercially available conjugate dyes were ranked in order of their relative brightness to 
each other. The brightest dyes such as PE, APC, PECy5.5 were reserved for antibodies to 
antigens that were known to be expressed at low levels and therefore stained dim, called 
tertiary antigens according to Mahnke and Roederer (2007) (eg. CCR5, CCR7). Primary 
antigens identify lineage markers of cells that have been well characterised and have distinct 
positive and negative populations (eg. CD3, CD4, CD8). Therefore dyes that are least bright 
such as FITC were used for these antibodies. The remaining dyes were selected for 
antibodies to CD28, CD95, CD27 and CD45RA for example, which bind to secondary 
antigens that are expressed by distinct subsets of cells. However, the separation between 
positive, negative and intermediate stained populations was less defined in this case and 
fluorescence-minus-one (FMO) controls were used to define gating amongst these 
populations.  
iii. Amount of fluorochrome spectral overlap   
One of the greatest challenges in flow cytometry is the overlap of emission spectra of 
individual conjugate or dyes (Baumgarth and Roederer, 2000). It is unlikely that emission 
filters measure signals from only one dye at a time. Instead, light from conjugates spill over 
into each other depending on the choice of fluorochrome and filters used. In the case of four 
colour flow cytometry, there are two lasers which reduces the amount of spectral overlap 
amongst most fluorochrome conjugates.  
iv. Commercial availability of the antibody-conjugate pair  
There are a limited amount of antibody-conjugate pairs that are cross-reactive to baboon 
and other nonhuman primates. As such, the choice of fluorochrome used was dependant on 
the availability the antibody of interest and whether or not it was manufactured from a cross-
reactive clone. Financial resource restrictions were also taken to account with the least 
















2.9. Titration of antibody-fluorochrome conjugates 
 
The optimal staining concentration is the minimum amount of antibody required to stain cells 
at the saturation point. Most manufacturers recommend that antibody fluorochrome 
conjugates should first be titrated to determine the optimal concentration needed to stain 
specific cell types. In addition, antibody-fluorochrome conjugates need to be titrated in order 
to optimise the separation of positive and negative populations.  
To determine the optimal concentration of antibody required to stain cells, all antibody 
conjugates were individually titrated by two-fold serial dilution.  The antibody conjugates 
were titrated starting from the initial volume of twice that recommended by the manufacturers 
and up to eight two-fold serial dilutions were setup for each antibody conjugate. The median 
fluorescence intensity (MFI) of the antibody-fluorochome conjugate at each concentration 
was used to generate a saturation curve. From these data, the concentration of antibody that 
results in the highest positive population, the lowest background caused by non-specific 
binding and at saturation point was selected as the optimal staining concentration (Perfetto 
et al., 2004).   
2.10. Staining protocol to exclude dead cells 
 
A marker of T cell viability was added to all panels involving multi-parameter (polychromatic) 
flow analysis using the BD LSR II Fortessa. The addition of a viability marker reduces false-
positive events and increases sensitivity for cytokine detection (Mahnke and Roederer, 
2007) since flurochromes bound to markers may bind non-specifically to dead cells or cells 
with a damaged membrane. For this study, a commercially available amine-reactive dye 
known as violet viability dye (ViViD) (Invitrogen) was used to stain dead cells. This dye binds 
to free amines in the cytoplasm of dead cells which do not have intact cell membranes 
(Perfetto et al., 2006; Perfetto et al., 2010). Live cells however, have intact cell membranes 
and ViViD will not stain these cells (hence the viable cells will be ViViD negative). ViViD is 
excited by the violet laser (407nm) and has the same emission wavelength as Pacific Blue 
(425-475nm), making it possible to use Pacific Blue- conjugated antibodies as a 
compensation control for ViViD.   
In brief, PBMC were dispensed into a sterile V-bottomed 96-well plate and washed twice 
with sterile 1x PBS (Gibco, Invitrogen) to remove any debris and proteins from the culture 
medium. This was achieved by spinning the plate in a centrifuge at RCF of 1000 xg (2100 













suspended in 1x PBS (200 µl/well) and the plate was centrifuged as before. To stain, the 
cells were re-suspended in ViViD (50 µl/well) at a pre-determined optimal concentration and 
the plate was incubated for 20 minutes at room temperature in the dark. Next, the cells were 
washed twice in FACS wash and pelleted by centrifugation (2100 rpm for 3 minutes), to 
remove unbound ViViD before surface staining. 
2.11. Surface marker staining protocol 
 
To identify the markers expressed on the cell surface (using the BD FACS Calibur or BD 
LSR II Fortessa), cells were re-suspended in pre-titred surface marker antibodies (to a final 
volume of 50 µl per reaction and were incubated for 25-30 minutes at room temperature in 
the dark. Excess antibody was removed by washing twice with FACS wash as described 
before (2.10 above). For the assays not proceeding to ICS, the cell pellets were re-
suspended in 1x CellFIX (BD Bioscience; 100 µl/well). CellFIX contains PBS with 4% 
paraformaldehyde which is converted to formaldehyde in this solution which preserves the 
molecular structure of the molecules in fixed positions within the cell matrix. The content of 
each well was then transferred into correspondingly labelled FACS tubes (BD BioScience). 
The FACS tubes were covered with aluminium foil to prevent light interference and kept in a 
refrigerator at 4°C for no longer than 48 hours or until acquisition. 
2.12. Intracellular marker staining protocol 
In order to stain for intracellular markers (e.g. IL-2, IFN-γ, TNF-α), cells were re-suspended 
with 100µl BD CytoPERM/CytoFIX (BD BioScience) per well for 20 minutes at room 
temperature. The cells were permeabilised to allow the antibody-fluorochrome conjugate 
markers to enter the cell and bind to intracellular markers within the cell. Since saponin-
mediated cell permeabilisation by CytoPERM/CytoFIX is a reversible process, the cells were 
stained and washed in PBS buffer containing saponin (BD Perm wash, BD Bioscience) The 
cells were washed twice and pelleted, as before, by centrifugation using 1x BD Perm wash. 
Thereafter, intracellular antibody mix comprising either a cocktail of antibody-conjugate 
markers of interest or individual antibody-conjugate markers at optimal staining 
concentrations, made up to a final volume of 50µl per reaction with 1x BD Perm/Wash, was 
added to each well. A well containing the same number of cells was also included as an 
unstained control. To this well, 50µl of BD Perm wash was added.  
Thereafter, the plate was placed away from light and the cells were stained for 25 to 30 
minutes at the optimal staining temperature conditions, usually at room temperature. Excess 













to centrifugation of the plate at 2100rpm for 3 minutes and this process was repeated. The 
supernatant was discarded before the addition of 100µl of 1x BD CellFIX (BD BioScience) 
per well. The contents of each well was mixed well by pipette and transferred into 
correspondingly labelled FACS tubes (BD BioScience). The FACS tubes were covered with 
aluminium foil to prevent light interference and kept in a refrigerator at 4°C for no longer than 
48 hours or until acquisition. The common reagents used to stain cells for flow cyotmetry 
analysis are described in Table 2.7. 
Table 2.7. Description of reagents used for staining of cells for flow cytometry 
Reagent Description Source 




FACS Wash buffer Buffer comprised of PBS with 1% FBS and 0.01% 
sodium azide as a preservative to prevent bacterial 
growth in buffer 
 
* 
Perm wash buffer Buffer comprised of PBS with FBS and saponin to 
maintain saponin-mediated cell permeabilisation of 
cells. Diluted to 1x solution with distilled water and used 




CytoPERM/CytoFIX Solution containing and formaldehyde and saponin 
which allows for the simultaneous fixation and 









   
* Prepared in the Primate Immunology Laboratory 
2.13. FMO Controls 
 
In order to gauge the sensitivity of the antibody conjugate in relation to each other and to 
distinguish amongst positive, intermediate and negative populations of certain antibodies, 
fluorescence-minus-one (FMO) controls were setup for each panel. An FMO control was 
setup such that PBMCs are stained with all but one antibody conjugates in the panel. A 
separate FMO that excluded each antibody conjugate present in the full panel was setup 
using baboon PBMCs which stained as per surface and intracellular staining protocols 














2.14. Compensation controls 
 
The process of compensation is a fundamental aspect of flow cytometry analysis involving 
more than two colours or parameters with different fluorochromes. The aim of compensation 
is to minimize overlap between spectral adjacent detectors such as that between FITC and 
PE or PE and PECy5 (Baumgarth and Roederer, 2000). This analysis requires the addition 
of compensation controls which are stained with individual antibody fluorochromes and 
should be included for every experiment conducted regardless of the panel used.  For four-
color flow cytometry analysis, PBMCs from the samples of interest were stained with each 
antibody according to either surface staining or intracellular staining protocols above. A 
compensation control was setup for each antibody used in a particular experiment and 
acquired separately.  This data was then used to generate a compensation matrix using 
FlowJo (Tree Star Inc, Ashland, OR). The compensation matrix was used to compensate the 
spectral overlap of all samples stained with multiple antibody-fluorochrome conjugates.  
2.15. The use of compensation beads as compensation controls 
 
Compensation controls were prepared by labelling anti-mouse or, in the case of IL-2, anti-rat 
antibody capture beads (Compensation beads) with individual antibody conjugates used in 
the panel.   Compensation beads were setup for every experiment by staining two drops of 
beads with the optimal volume of antibody conjugate. Beads were stained for 5 to 10 
minutes at room temperature and 100µl of FACS wash was added to beads prior to fixation 
with 100µl 1x BD CellFIX (BD BioScience). The stained beads were analysed on the BD 
Fortessa and the data obtained was used to calculate a compensation matrix using FlowJo 
analysis. An unstained control which comprised of beads only was included and used to gate 
on negative populations during the setup of the compensation matrix.     
2. 16. Data acquisition and analysis 
 
During flow cytometry analysis using the four colour BD FACS Calibur, an average of 50 000 
events based in the lymphocyte gate were analysed per sample using BD Cell Quest, 
version 5.1 (BD BioScience) and data analysis was performed using FlowJo (Tree Star Inc, 
Ashland, OR) analysis software. For four colour flow cytometry analysis, samples were 
analysed and compensated using FlowJo compensation matrices. For polychromatic flow 
cytometry analysis using the BD Fortessa an average of 250 000 events were acquired per 
sample using BD Diva (BD BioScience) and were analysed using FlowJo analysis software. 













events per compensation control) and were used to generate FlowJo compensation 
matrices. 
2.17. Statistical analysis 
 
Statistical analyses for non-parametric one way ANOVA (Kruskal-Wallis), mean and 
standard deviation calculations were performed using Graph Pad Prism version 6.0 for 
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3.1 Introduction and background 
 
Memory T cells differ from naïve T cells in their specific expression of surface markers, 
homing markers and functional capacity. As reviewed Sallusto et al., 2004, naïve T cells 
express homing markers such as CD62L and CCR7 that limit them to lymphoid tissues, high 
levels of co-stimulatory molecules such as CD27 and CD28 and have limited (almost no) 
ability to produce cytokines. These cells are not antigen experienced and therefore do not 
express markers of T cell activation such as CD25, CD44, HLA-DR or CD69 (Akbar et al., 
1991, De Rosa et al., 2001).   Like naïve T cells, the central memory population has the 
ability to occupy lymphoid tissues and expresses co-stimulatory molecules. Unlike naïve T 
cells however, the central memory T cells secrete proliferation inducing cytokines such as IL-
2. Effector memory T cells (Tem) constitute the first line of defence at the portals of 
pathogen entry and function to rapidly secrete significant amounts of anti-viral and anti-
bacterial cytokines such as IFN-γ and TNF-α. These cells which have now differentiated to 
persist in the periphery and mucosal sites express adhesion molecules such as CD11a 
instead of lymphoid homing molecules (Dutton et al., 1998). Effector memory T cells are 
usually considered as mature T cells which have the ability to undergo apoptosis and 
express CD95, but do not express co-stimulatory molecules. 
 
3.1.1. Markers of memory T cell populations 
 
The identification of naive and memory T cell populations are based on the relative 
expression of several surface and functional markers which convey the tissue homing status, 
level of differentiation, antigen experience and functional capacity of the cell. The 
characterisation of T cell memory subsets using a number of commercially available markers 
have been extensively studied in humans, rhesus macaques and mice.  
 
Tissue homing markers such as CCR7 together with adhesion markers CD62L (L-selectin), 
CD44 (H-CAM) and lymphocyte fusion antigen 1 (LFA-1) mediates the entry of T cells via 
high endothelial venules (HEVs) into secondary lymphoid tissues (Campbell et al., 2001). 
These markers have been used to differentiate between naive and memory T cells (Sallusto 
et al., 1999).  It has been previously demonstrated in mice that naive T cells have a 
CD62LhiCD44lo phenotype, whereas memory T cells exhibit a CD62LloCD44hiphenotype 
(Wherry et al., 2003). Other marker combinations previously used to define T cell 
phenotypes such as CD45RA and/or CD45RO and the lymphoid homing marker, CCR7, 













CD45RO+) and Tem (CCR7-CD45RA-CD45RO+) (McLaughlin et al., 2008; Sallusto et al., 
1999).  The type of cytokines produced and the frequency of cytokine producing cells have 
also been used to characterise memory T cell phenotypes. It is accepted that naive T cells 
do not produce cytokines IL-2 and IFN-γ, whilst Tcm produce high levels of IL-2 and Tem 
produce high levels of IFN-γ and TNF-α (Sallusto et al., 2004).  
 
Co-stimulatory molecules expressed at the surface of T cells such as CD28 and CD27 have 
also been used to classify T cell memory populations (Weekes et al., 1999, Tomiyama et al., 
2002). During antigen presentation, CD28 engages with molecules on the surface of APCs 
such as CD80 and this is a fundamental step in T cell activation (Lenschow et al., 1996; 
Howland et al., 2000). T cells which will be in direct contact with antigen presenting cells, 
such as naive and Tcm cells, express CD28. Unlike CD28, the function of CD27 is less well 
defined but it is known that the expression of this molecule is enhanced during antigen 
presentation and that it is probably involved in the expansion of memory cells (Hendricks et 
al., 2005; Borst et al., 2005). The results of previous studies highlight that CD45RA, CCR7 
and CD27 can be used in combination to define T naive cells as CD45RA+CCR7+CD27+, 
Tcm as CD45RA-CCR7+CD27+ and Tem as CD45RA+CCR7-CD27- (Mercier et al.,2008; 
Tilton et al., 2007).  
 
 The Fas ligand receptor, CD95, is expressed on cells programmed to undergo apoptosis 
and has also been used in combination with either markers of maturation (CD45RA or 
CD45RO) (Mattapallil et al., 2005) or co-stimulatory markers such as CD27 and CD28 to 
characterise T cell memory phenotypes in rhesus macaques (Pitcher et al., 2002). It has 
been shown that CD95 regulates T cell homeostasis of peripheral memory T cells (Arens et 
al., 2005, Mogil et al., 1995). In the rhesus macaque model, a combination of CD28 and 
CD95 has been used to delineate naive T cells (CD28+ CD95-) from Tcm (CD28+CD95+) 
and Tem (CD28-CD95+) (Sun et al., 2005; Letvin et al., 2006; Sun et al., 2009). To date, the 
use of CD28 and CD95 in combination has not been reported for the memory phenotype 
analysis of T cells from Chacma baboons. 
The Chacma baboon is widely available in Southern Africa and could be used as a predictive 
model for preclinical studies investigating vaccine efficacy, immunity and pathogenesis. 
Despite this however, there are limited studies that have evaluated T cell memory 
phenotypes in the Chacma baboon model. As such, there are no widely accepted memory 
markers which can be used to accurately and effectively define T cell memory phenotypes in 













In this study, T cell memory markers were investigated for cross-reactivity to select those 
that are suitable for inclusion in flow cytometry analysis of T cell memory phenotypes. The 
objectives of this chapter are to select a combination of memory markers that are suitable for 
inclusion in a flow cytometry panel of antibodies to investigate T cell memory phenotypes 
using baboon PBMC and to examine the characteristics of T cell memory subset delineated 
by the selected combination of markers to determine if they are similar to those of typical 
phenotypes. 
 
3.2 Specific objectives  
 
3.2.1. Identify and evaluate various anti-human antibodies to select a suitable combination of 
markers to detect T cell memory subsets in baboon PBMCs. 
 
3.2.2. To determine the suitability of the selected markers by investigating the functional, 
activation and maturation characteristics of the baboon T cell memory phenotypes defined 































3.3. Material and methods 
3.3.1. Samples 
 
Cryopreserved PBMCs isolated from unvaccinated, healthy Chacma baboons were used in 
this study to select suitable markers to investigate T cell memory by flow cytometry analysis. 
The PBMCs were thawed according to the protocol outlined in Chapter 2. For assays used 
to detect activation markers or cytokine production, the PBMCs were rested for 4-6 hours 
and stimulated with SEB as described in Chapter 2.  
3.3.2. Cross-reactivity of clones of anti-human antibodies with baboon PBMCs 
 
Several commercially available clones of anti-human antibodies which are known to detect 
CD28, CD95, CD27, CD45RA, CD69, CCR7 and CCR5 in humans and/or rhesus macaques 
were tested for cross-reactivity with baboon PBMCs. For cross-reactivity testing, PBMCs 
isolated from baboons were stained with individual clones of antibodies using the 
manufacturer’s recommended concentrations and staining conditions. Flow cytometry was 
then used to determine cross-reactivity. Lineage markers CD3, CD4 and CD8 were also 
included for gating purposes. Cross-reactivity of several clones of these markers, together 
with markers for the cytokines IL-2, IFN-γ and TNF-α have already been demonstrated in the 
baboon model (Casimiro et al., 2003; Chege et al., 2005; Chege et al.. 2008; Burgers et al., 
2009).  
Antibody clones that provided a distinct signal for both the antibody negative and positive 
populations (bimodal expression of markers) in accordance to the manufacturers 
recommendations were considered cross-reactive. For antibody markers which had 
overlapping positive and negative population, such as CD45RA and CD95, isotype controls 
were used as a control to stain cells. Isotype controls are matched to the antibody 
flourochrome conjugate of interest and they are conjugated to the same fluochrome but bind 
to all cells that express the same fragment crystalizable (Fc) receptor of the antibody 
(Maecker and Trotter 2006). Isotype controls are used to determine the level of non-specific 
binding of fluorochromes (Maecker and Trotter 2006). In this way, positive population of cells 















3.3.3. Optimisation of staining temperature used for four-colour flow cytometry 
 
To determine the optimal staining temperature that ensured optimal antibody -conjugate 
binding to its corresponding cellular marker, PBMCs from unvaccinated baboons were 
stained at either 37°C (37degC), room temperature (RT) or on ice with antibodies at 
manufacturer’s recommended concentrations. Positive populations were gated according to 
the recommendations made by the manufacturer and by considering the unstained cells.  
3.3.4 Titration of antibodies 
 
The optimal staining concentration of each antibody-fluorochrome conjugate was determined 
by staining baboon PBMCs with two-fold serial dilutions starting from twice the 
manufacturers’ recommendations. The titration of each antibody was performed according to 
protocols detailed in Chapter 2. 
3.3.5. Selection of a suitable combination of T-cell memory markers using four-
colour flow cytometry. 
 
The principles used to assign antibodies to fluorochrome markers and to select combinations 
of antibody-fluorochrome conjugates to limit spectral overlap are detailed in Chapter 2. In 
this study, CD95 was combined with CD27, CD28 or CD45RA in a four colour antibody panel 
to select a combination that displayed the best separation of memory subsets for both CD4 
and CD8 subsets. The combinations of memory markers tested in this study are detailed in 
Table 3.1. 
Table 3.1. Flow cytometry panels designed for the selection of maturation markers to 
identify T cell memory phenotypes in PBMCs isolated from Chacma baboons. 











Panel B CD45RA 
CD95 
CD3 





Panel C CD27 
CD95 
CD3 


















3.3.5. Characterisation of memory phenotypes defined by the CD28 and CD95 
flow cytometry panel in baboon PBMCs. 
 
At the time this study was started, the CD28 and CD95 antibody markers had not been used 
for the memory phenotype analysis of T cells from baboons. However, these markers have 
been used to define memory phenotypes in other nonhuman primate models such as the 
rhesus macaque (Sun et al., 2005; Sun et al., 2009). In order to determine the suitability of 
these markers, CD28 and CD95 were used to stain PBMCs from five unvaccinated animals. 
In addition, other markers of T cell maturation (CD45RA PE), activation status (CD69 PE) 
and cytokine production (IL-2 PE, IFN-γ PE) were also included in individual panels. These 
additional markers were used to further characterize the memory subsets of CD4+ and 
CD8+ T cells with the intention to confirm whether these subsets are accurately defined by 
CD28 and CD95.  Table 3.2 details the validation panels used in this study.  
For the flow cytometry panels which included functional markers (cytokines), cells were first 
stimulated with SEB for a total of 16 hours and after the first 2 hours, BFA was added. Since 
BFA has been reported to prevent the expression of surface CD69 (O’Neil-Andersen and 
Lawrence, 2002),  the cells were first stimulated with SEB for 16 hours and after the first 2 
hours, BD GolgiStop (BD Biosciences) containing monensin was added. The cells were then 
stained and fixed using the surface and intracellular staining protocols above. For all 
experiments, the cells were analysed using the FACS Calibur. 
Table 3.2. Flow cytometry panels designed to determine the suitability of CD28 and 
CD95 to define T cell memory phenotypes in PBMCs isolated from Chacma baboons.  
















































3.3.5.1. Gating strategy and data analysis 
 
On average, 50 000 events gated on the lymphocyte population for each experiment, and 
5000 events from the compensation controls (Chapter 2) were analysed by flow cytometry 
(FACS Calibur) using BD Cell Quest, version 5.1 (BD BioScience). Data analysis and 
compensation was performed in FlowJo (Tree Star Inc, Ashland, OR). The overall gating 
strategy employed for the validation experiments in this chapter are illustrated in Figure 3.1. 
The frequency (%) of expression of the markers CD45RA, IL-2, IFN-γ and CD69 by naive 
and memory T cells were then determined.  
 
 
Figure 3.1. Gating strategy used for FACS Calibur analysis of PBMCs isolated from a 
representative healthy baboon (sample B363).  Firstly, the lymphocyte population was isolated by 
the relative size and density of PBMCs gated by analysing forward Scatter (FSC-H) and side scatter 
(SSC-H). Then, CD4+ or CD8+ T-cells were gated by using either SSC-H versus CD4 or CD8 
respectively.  The memory phenotype of both CD4 and CD8 positive T-cells were then gated using 
CD28 vs CD95 (memory markers).  For the validation of the panel, each subpopulation (Tnaive, Tem 
and Tcm) as defined by the CD28 vs. CD95 panel, were further characterised in terms of their relative 
expression of CD45RA, IL-2, IFN-γ and the activation marker CD69. 
3.3.5.2. Statistical analysis 
 
The expression of CD45RA, IL-2, IFN-γ and C69 were compared amongst T naive, Tcm and 
Tem using non-parametric one way ANOVA (Kruskal Wallis) followed by Dunn’s multiple 














3.4.1. Cross-reactivity of clones of anti-human antibodies with baboon PBMCs 
 
Distinct populations of positive staining cells were determined by analysis of histograms 
representing the stained baboon PBMCs (Figure 3.2). The unstained control was used to 
define positive versus negative cell populations. For cytokine bound conjugates, the positive 
population was distinguished from the negative population by using unstimulated controls. In 
this study, antibody markers of CD28 (clone CD28.2), CD95 (DX2), CD27 (clone M-T271), 
CD45RA (clone 5H9), and CD69 (clone FN50) were found to be cross-reactive in PBMCs 
isolated from healthy, unvaccinated Chacma baboons (Table 3.3). In addition, HLA-DR 
(clone G46-6) was also found to be cross-reactive but was not used in the remainder of the 
study. The cross-reactivity of several clones of CD3, CD4, CD8, TNF-α, IL-2 and IFN-γ were 
also confirmed (Table 3.3). However, cross-reactivity of CCR7 (clone 150503) and CCR5 
(clone 3A9) to Chacma baboon PBMCs were not observed and these markers were 
therefore not used for further analysis in this study.   
 
Figure 3.2. Cross-reactivity of antibody markers with PBMCs isolated from Chacma baboons. 
PBMCs were stained with antibody markers in accordance with the manufacturers’ recommendations.  
Representative antibody-conjugates found to be cross-reactive in PBMCs isolated from unvaccinated 
healthy baboons A) CD27 PE clone M-T271 and B) CD45RA PE clone 5H9.  In addition, an example 

















Table 3.3.  Optimal staining concentrations (per 1x106 cells in 50ul) and conditions, cross-reactivity and clone of antibody-conjugates for FACS 
Calibur flow cytometry analysis using lymphocytes from PBMCs isolated from baboons. 
 
Marker Clone Flourochrome Source Manufacturer’s recommended concentration 
(µl/100ul)   
Optimal conc. 
 
CD3 SP34-2 PerCP BD 20µl 3µl 
FN-18 FITC BioSource 20-50µl 1µl 
CD4 
 
L200 PerCP BD 20µl 3µl 
L200 APC BD 20µl 1µl 
CD8 
 
SK1 PerCP BD 20µl 3µl 
SK1 APC BD 5µl 1ul 
CD28 CD28.2 PE BD 20µl 1µl 
CD28.2 APC BD 20µl 1µl 
CD28.2 FITC BD 20µl 1µl 
CD95 DX2 PECy5 BD 20µl 1µl 
DX2 FITC BD 20µl 1µl 
DX2 APC BD 20µl 1µl 
CD45RA 5H9 PE BD 20µl 5µl 
5H9 PECy5 BD 20µl 2.5ul 
CD27 M-T271 PE BD 20µl 1.25µl 
M-T271 APC BD 20µl 1µl 
 M-T271 FITC BD 20µl 1.25µl 
CD69 FN50 PE BD 20µl 2.5µl 
IL-2 MQ1-17H12 PE BD 20µl 2µl 













3.4.2. Optimisation of staining temperature used for four-colour flow cytometry 
 
To determine which staining temperature would allow for optimal antibody binding, minimal 
background and maximum detection of rare event populations, the relative frequency of 
lymphocytes that were positive and negative for the antibody of interest were determined by 
four colour flow cytometry analysis. The PBMCs from healthy, unvaccinated baboons were 
stained at either 37°C (37degC), room temperature (RT) or on ice (Figure 3.3).  The optimal 
staining condition was determined by comparing the relative frequency of the positive 
population taking into account the lowest background (non-specific fluorescence) 
represented by the unstained control. 
Most of the markers tested, optimally stained baboon PBMCs at both room temperature and 
on ice but not at 37°C with the exception of CD95 PECy5. Specifically, CD3-PerCP,-FITC 
and CD45RA-PE were optimally stained on ice, whilst CD4-APC and CD27-PE stained 
optimally at room temperature. Since a higher level of non-specific fluorescence was 
observed at 37ºC compared to that at room temperature and the lowest level of background 
staining was observed at room temperature (+/- 23 to 27 ºC) these results suggest that 
baboon PBMCs could be stained with these markers at room temperature. 
 
Figure 3.3. Optimisation of staining conditions for PBMCs isolated from Chacma baboons. 
Cryopreserved PBMCs isolated from unvaccinated, healthy baboons were stained with antibody 
markers on ice (blue bars), at room temperature (green bars) or 37°C (red bars). Bar graphs show the 
frequency (%) of positive populations after cells were gated according to SSC and FSC gates.  An 
unstained reaction was also included at each staining condition as a negative control to account for 






































































3 7 d e g C









































3.4.2. Titration of antibodies for four colour flow cytometry 
 
It is widely accepted that the optimal concentration (and hence volume) of antibody 
conjugate used for flow cytometry analysis affects the overall quality of the data in terms of 
spectral overlap, compensation and accuracy. Therefore all commercial antibody conjugates 
were individually titrated by two-fold serial dilution to determine the optimal antibody 
concentration required for staining baboon PBMCs (Figure 3.4). The MFI of the positive 
staining population, as determined by flow cytometry analysis was plotted against the 
concentration of antibody conjugate used in a two-fold serial dilution as described in (Figure 
3.4 B) Chapter 2. 
 A saturation curve of antibody-specific isotype controls indicate the MFI of the level of 
background or non-specific staining observed at particular antibody concentrations for some 
antibody-conjugates. The optimal antibody conjugate volume and concentration was typically 
found at the saturation point or just below saturation point depending on the level of 
background at that titre. A summary of the optimal staining volume of the antibody 






































Figure 3.4. Representative antibody titration and saturation curve. Cryopreserved PBMCs 
isolated from healthy Chacma baboons were stained with CD27 PE in a two-fold serial dilution. (A) 
Flow plots show the two-fold serial dilution series with the concentration of antibody used for surface 
staining. Cells were first gated on lymphocytes based on their side scatter and forward scatter 
properties. (B) CD27 PE titration saturation curve (blue line) constructed by comparing the median 
fluorescence intensity (MFI) of the positive populations of lymphocytes (Ab concentration). Saturation 
curves of antibody-specific isotype controls (red line) indicate the MFI of the level of background or 
non-specific staining observed at particular antibody concentrations. For each antibody pair, optimal 
staining concentrations were determined at or just below the level of saturation. 
20ul 10ul 5ul 2.5ul













































































3.4.3. Selection of a suitable combination of T-cell memory markers using four-
colour flow cytometry. 
 
Three 4-colour flow cytometry antibody panels that included a combination of anti-CD95 with 
anti- CD27, -CD28 or -CD45RA were tested to determine which combination of memory 
markers was most suitable to include in a final panel for the analysis of memory responses 
in PBMCs isolated from baboons. As shown in Figure 3.5, CD45RA and CD95 allowed for 
the separation of CD4+ and CD8+ naive T cells (Tnaive: CD4RA+CD95-) and Tem 
(CD45RA-CD95+) but a clear Tcm population was not distinguishable.  The CD27 and CD95 
markers separated naive T cells (CD27+ CD95-) from Tcm (CD27+CD95+) and Tem (CD27-
CD95+) but the separation was not as clear as the CD28 and CD95 combination.  Using this 
panel, the memory phenotypes were defined as central memory (Tcm; CD28+CD95+) and 
effector memory (Tem; CD28-CD95+) populations with the naïve T cells being defined as 
(CD28+CD95-). The CD28 and CD95 marker combination was therefore selected for 
inclusion in a flow cytometry panel to further investigate T cell memory phenotypes in 
PBMCs from Chacma baboons. 
 
 
Figure 3.5 T cell memory marker combinations used for flow cytometry analysis of PBMCs 
isolated from a healthy unvaccinated baboon. Cryopreserved PBMCs were stained with several 
markers used together with CD95 to identify distinct subpopulation separation amongst T cell memory 
phenotypes. These combinations included A) CD45RA and CD95, B) CD27 and CD95 and C) CD28 
and CD95. Cells were first gated on lymphocyte populations based on FSC and SSC properties, then 


















3.4.4. Characterisation of memory phenotypes defined by the CD28 and CD95 
flow cytometry panel in baboon PBMCs. 
 
Having shown that the CD28 and CD95 combination was the most suitable for inclusion in a 
multi-colour flow cytometry panel, the distribution of memory phenotypes in CD4+ and CD8+ 
T cell memory populations were determined for n=5 healthy, unvaccinated Chacma baboons 
by comparing the relative expression of CD28 and CD95.  
Using this antibody combination, the mean frequencies (±SD, n=5) of CD4 naïve, Tcm and 
Tem were 49.2±12.3%, 27.3±9.8%, 16.8±2.4%, respectively. The mean frequencies (±SD, 
n=5) of CD8 naive, Tcm and Tem were 37.0±16.2%, 17.6±6.4%, 42.5±8.3%, respectively 
(Figure 3.6). There was no significant variation in the frequencies of memory subpopulations 
in both CD4+ and CD8+ T-cells. However, there were a higher number of Tem cells in the 






















Figure 3.6. Mean frequency (n=5) of naïve, central and effector memory T-cell populations 
defined by CD28 and CD95 memory markers. Cryopreserved PBMCs isolated from healthy 
baboons were defined by the CD28 and CD95 memory panel as naïve (Tnaive: CD28+CD95-), 
central (Tcm: CD28+CD95+) and effector (Tem: CD28-CD95+) memory T-cell populations. Cells were 
first gated on lymphocyte populations based on their SSC and FSC staining properties. Then CD4+ 
and CD8+ cells were identified and further gated into memory populations using CD28 and CD95. 
The graph shows the mean frequency of CD4+ Tnaive, Tcm and Tem (red) and CD8+ T naive, Tcm 
and Tem (blue). A larger ratio of CD4+ T cells were defined as Tcm compared to that of CD8+ whilst 
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Figure 3.7. Characterisation of memory phenotypes defined by the CD28 and CD95 marker 
combination in baboon PBMCs.  PBMCs from baboons (n=5) were stained with CD28, CD95, CD4 
or CD8 and either CD45RA, IL-2, IFN-γ or CD69. The bar graphs represent the relative proportion (%) 
of A) CD45RA, B) IL-2, C) IFN-γ and D) CD69 expression on both CD4+ and CD8+  naïve (Tnaive, 
green bars), central memory (Tcm, blue bars) and effector memory (Tem, red bars) phenotypes 
defined by CD28 and CD95. Statistically significant differences in expression are indicated as 













Further characterisation sought to determine if the T cell memory subsets based on CD28 
and CD95 exhibited the expected functional, maturation and activation characteristics. The 
memory subsets delineated using the CD28 and CD95 memory markers were therefore 
investigated for functional capacity (expression of intracellular IFN-γ and IL-2) and activation 
status (expression of CD69) in response to staphylococcus enterotoxin B (SEB) stimulation. 
In addition, the expression of CD45RA, a marker for naïve T cells, was also investigated 
(Figure 3.7). 
The maturation marker, CD45RA, was detected on a large percentage with a mean± 
standard deviation of 78.82% ± 11.17 on naïve CD4+ and 96.84% ± 1.94 on naive CD8+ 
cells. This marker was expressed in a significantly (p≤0.001) smaller proportion of CD4+ 
(7.07% ± 2.05) and CD8+ (26.36%± 16.76) Tcm cells. In Tem, CD45RA expression was 
significantly lower compared to naive T cells (p≤0.05%) with a mean expression of 
3.58%±1.62 and 26.84% ±13.45 in CD4+ and CD8+ Tem respectively. Upon SEB 
stimulation, a significantly higher proportion of CD4+ Tcm (13.8%±4.1) compared to Tem 
(4.6%± 1.7) (p≤0.05) and naive T cells (1.9%±1.2) (p≤0.01) expressed IL-2. In the CD4+ 
compartment, Tem produced significantly more (p≤0.01) IFN-γ (mean of 17%±4.7) 
compared to naive T cells which expressed this marker at a mean of 2.2%±0.7. CD4+ Tem 
expressed more IFN-γ compared to CD4+ Tcm (mean 8.0% ±2.6) although this was not 
statistically significant. In the CD8+ compartment Tem produced significantly more (p≤0.05) 
IFN-γ (mean of 18.5%±7.3) compared to naive T cells which expressed this marker at a 
mean of 2.0%±1.3. CD8+ Tem also expressed more IFN-γ compared to CD8+ Tcm (mean 
7.2%±2.3). In the CD4+ compartment, CD69 was expressed on 20.5%±11, 30.8%±3.1 and 
27.9%±13 of naive, Tcm and Tem populations respectively (Figure 3.7). 
3.5 Summary of key findings 
 
Several commercially available anti-human antibodies were tested for cross-reactivity using 
PBMCs isolated from healthy, unvaccinated Chacma baboons. Antibody markers of CD28 
(clone CD28.2), CD95 (DX2), CD27 (clone M-T271), CD45RA (clone 5H9), HLA-DR (clone 
G46-6) and CD69 (clone FN50) were found to be cross-reactive, however cross-reactivity of 
CCR7 (clone 150503) and CCR5 (clone 3A9) was not observed. These markers were 
removed from further analysis. 
It was found that antibody markers stained baboon PBMCs optimally at room temperature. 
Staining cells at room temperature also had the added advantage of limited background 
(non-specific) staining. In addition, antibody conjugate markers were titrated using baboon 













Several combinations of memory markers including CD45RA/CD95, CD27/CD95 and 
CD28/CD95 were evaluated to determine the most suitable combination to delineate 
memory T cell phenotypes in PBMCs isolated from Chacma baboons. It was found that the 
CD28/CD95 combination provided the most distinct separation of naive, central memory and 
effector memory T cells in both CD4+ and CD8+ compartments. 
The CD28 andCD95 marker combination was then further characterised by investigating 
whether the phenotypes delineated by these markers displayed expected levels of 
maturation, activation and functional capacity. The expression of the maturation marker 
CD45RA, cytokines IL-2 and IFN-γ and the early activation marker CD69, by each memory 
phenotype delineated by the CD28/CD95 markers was determined using four-colour flow 
cytometry. CD45RA expression was significantly higher in both CD4+ and CD8+ naive T 
cells compared to Tcm and Tem.  The production of IL-2 by CD4+ Tcm was significantly 
higher compared to naive T cells and Tem cells. In the CD8+ compartment, IL-2 production 
was higher in the Tcm population compared to the naive T cell population (p≤0.01) and Tem. 
CD4+ and CD8+ Tem cells produced more IFN-γ than the naive T cell population (p≤0.01 
and p≤0.05 respectively) and Tcm populations. The expression of CD69 was higher in CD4+ 
and CD8+ memory T cell populations compared to naive T cells although this was not 
statistically significant.  
In conclusion, the selected CD28 and CD95 markers used in combination was characterised 
and these markers were found to be suitable for inclusion in a multi-parameter flow 
cytometry panel to investigate the distribution of memory T cell phenotypes using PBMCs 













































Chapter 4.  Investigation of vaccine specific T cell 
memory responses in Chacma baboons vaccinated with 
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4.1.  Introduction and background 
 
 In the absence of sterilising immunity, HIV-1 vaccines should aim to have the ability to 
induce vaccine specific immune responses to limit infection, prevent the replication of viral 
particles so as to reduce escape mutant formation and to achieve a sustained level of 
protection (Robinson and Amara, 2005). In order to accomplish this, HIV-1 vaccines should 
induce adaptive T cell immune responses with the aim to generate long lived, HIV-1 specific 
memory recall responses (Robinson, 2007).   These memory responses whether in the form 
of central memory T cells (Tcm) or effector memory T cells (Tem) should work in synergy to 
generate a robust, effective and HIV-1 specific immune response upon infection (Sallusto et 
al., 2004). The distribution of memory T cell phenotypes and the maintenance of memory T 
cells depend on the type and amount of vector and HIV-1 immunogen delivered and is 
heralded as a crucial measure of vaccine efficacy (Pillai et al., 2011).  In this study, the 
presence, persistence and distribution of memory T cell phenotypes in Chacma baboons 
vaccinated with either SAAVI MVA-C prime followed by VLP boost or DNA prime followed by 
VLP boost regimens was investigated using flow cytometry analysis.  
4.1.1. T cell memory 
 
T cell memory is defined as long lived responses that can be initiated long after the initial 
exposure to antigen to induce a robust, strong secondary immune response to the same 
antigen upon re-encounter (Dutton et al., 1998).  In the naive host, there is a large proportion 
of naive T cells with the potential to commit to apoptosis or differentiation into effector and 
memory populations once antigenic and co-stimulatory signals are received by either 
immunisation or infection (Matloubian et al., 1994; Kaech et al. 2002) The differentiation of 
the naive T cells depends on the strength of the signal received and the milieu of cytokines 
generated in response to antigenic stimulation (Lanzavecchia and Sallusto, 2005). Naive T 
cells that are committed to differentiation into effector or memory T cells change the profile of 
their gene expression and in turn, the expression of molecules on their surfaces.   
Naive T cells and some terminally differentiated T cells express the surface marker CD45RA 
(CD45RA+) in contrast to memory T cells which express a different isoform of CD45 known 
as CD45RO (CD45RO+) (reviewed in Esser et al., 2003). In addition, naive T cells are 
housed in the lymphoid tissues and therefore express L-selectin (CD62L) and CCR7 (Picker, 
1993). These cells have the ability to readily proliferate upon encountering antigens or during 
depletion of T cell pools and therefore produce low levels of IL-2 during in vitro stimulation 













 Effector and memory T cell subsets can be defined by the phenotypic and functional 
changes that arise from their previous interactions with antigens. Two distinct memory T cell 
populations namely effector memory (Tem) and central memory (Tcm) have been defined on 
the basis of the expression of lymphoid homing markers, CD62L and CCR7 (Sallusto et al., 
1999), but it now clear that the definition of memory phenotypes is more complex than this 
dogmatic definition (Wherry and Ahmed, 2004).  
The classification of another subset of CD8+ memory T cells known as terminally 
differentiated cells with the phenotype of CD45RA+CD62L-CCR7- where initially referred to 
as RA+ effector memory T cells because these cells produce perforin, IFN-γ and TNF-α, are 
cytotoxic, and are capable of rapid effector function after stimulation (Sallusto et al., 1999; 
Tussey et al., 2000). Recently, a new long lived T cell memory phenotype similar to naive T 
cells in terms of phenotypic expression of CD45RO−, CCR7+, CD45RA+, CD62L+, CD27+, 
CD28+ and IL-7R+, self renewal capacity, multi-potent ability to differentiate into effectors, 
and other memory phenotypes has been identified in mice (Gattinoni et al., 2011). Despite 
being similar to naive T cells, these stem cell-like memory T cells however, also express 
CD95 and have many functional attributes synonymous to memory T cells (Gattinoni et al., 
2011). It is therefore becoming increasingly clear that even T cell differentiation may not 
occur as linearly as expected.  
4.1.1.2. Models of memory T cell differentiation  
 
Numerous models of T cell differentiation have also been proposed and it remains unclear 
as to which model best explains the process of T cell differentiation. Regardless of the most 
acceptable model of differentiation, it is now clear that the level of memory cell differentiation 
is dependent on the initial T cell frequency, clonal competition of T cell repertoires and the 
strength and persistence of the initial antigen stimulus (Bouneaud et al., 2005; Jabbari and 
Harty,  2006; Badovinac et al., 2007).  
 According to the linear model of T cell differentiation (Figure 4.1 A), after exposure to an 
antigen (and in the presence of co-stimulatory and cytokine signals), naïve T-cells undergo 
differentiation and proliferation which results in the development of effector functions; alter 
their ability to proliferate and change their homing tissue profiles (Oehen and Brduscha-Reim 
1998). These changes usually result in the expression of subset specific cell surface 
markers that are used to monitor and define the production of memory T cell subsets as well 
as effector T cells. The majority (>90%) of antigen experienced effector T cells will undergo 
apoptosis during the contraction phase of the T cell response. It is theorised that the 













cells (CCR7- and CD62Llow), which have the ability to induce a robust and highly focused 
response to the antigen. These effector memory T cells can give rise to long-lived central 
memory T cells that are CCR7+ and CD62L+, and proliferate in lymphoid tissues.  Upon 
encountering the same antigen (either in the form of challenge or infection), memory T cells, 
rapidly proliferate and further differentiate generating a large population of antigen specific T 
cells.    
Another possible model of memory T cell differentiation known as the bifurcative 
differentiation model (Figure 4.1 B), describes the formation of cells with multiple 
differentiation fates from one naive T cell. This occurs through asymmetric cell division 
following antigen stimulation (Gerlach et al., 2010). These cells can either yield effector cells 
that undergo apoptosis after antigen clearance, long-lived Tcm or Tem cells. The self-
renewing effector model of memory T cell differentiation (Figure 4.1 C) or decreasing 
potential hypothesis, proposes that naive T cells can either differentiate into Tcm cells or 
self-renewing effector T cells which express lymphoid homing markers and proliferation. This 
model suggests that these cells then can further differentiate into non-self renewing Tem 
cells which migrate to sites of infection or become senescent terminally differentiated 
effector T cells (Fearon et al., 2001).  
4.1.1.3. Factors that influence the distribution of memory T cell populations 
 
The differentiation and maintenance of memory T cells is a crucial measure of vaccine 
immunogenicity. The expansion, contraction and differentiation of antiviral memory T cells 
following antigen exposure is strongly influenced by several factors such as antigen 
presenting cell driven signalling and the cytokine production which is in turn are dependent 
on the PRRs (Schluns and Lefrancois, 2003). The particular PRR which is engaged is 
influenced by the type of viral, bacterial or antigenic material presented to antigen presenting 
cells (Pulendran, 2006; Querec et al., 2006).  
 
In terms of vaccine development, the functional quality and quantity of CD4 and CD8 
memory populations differ according to which type of vectors (recombinant viral or bacterial, 
or DNA) delivers antigen to the host (Pillai et al., 2011). It is also evident that the type of 
immunogen encountered, the age of the host and the persistence of the antigen also 
determines the predominant memory phenotype. Studies in mice, NHPs and humans have 
clearly shown that the distribution of memory phenotypes change with age. The number of 
naive T cells eventually decrease from childhood to adulthood whereas the establishment of 
memory T cells increase (Linton and Dorshkind, 2004; Nikolich-Zugich, 2008). This is 













time as the host ages. The distribution of memory populations differ in the CD4+ and CD8+ 
T cell compartments as well as in specific tissues. CD4+ T cells in human peripheral blood 
are skewed towards Tcm and CD8+ skewed towards Tem (Sallusto et al, 1999). 
Furthermore, whilst a large proportion of T cells from lymphoid organs and tissues are 
enriched with cells from the Tcm phenotype, gut, lung, liver and reproductive tissues have 
more Tem cells (Campbell and Butcher, 2002).   
 
Figure 4.1 Proposed models of memory T cell differentiation. A) The linear differentiation model 
of memory T cell differention, B) The bifurcative differentiation model of memory T cell differention 














4.1.1.4. T cell memory populations and HIV vaccine efficacy 
 
Investigation of the T cell responses induced by successful vaccines against other human 
diseases such as tetanus, yellow fever and small pox demonstrate that stable long-lived 
CD4+ and CD8+ memory T cells are associated with long-term protection (Cellerai et al., 
2007; Miller et al., 2008). The same hypothesis can be applied to vaccines against HIV-1. 
The characterisation of T cell memory subsets is therefore an essential measure of the 
immunogenecity of candidate HIV-1 vaccine. Studies have shown that HIV controllers were 
able to preserve the number of Tcm cells which were able to produce interleukin-2 (IL-2) 
(Potter et al., 2007). In addition, Tem cells of these controllers were polyfunctional and 
reportedly secreted as much as three times more cytokines that expected in HIV-1 infected 
individuals (Potter et al., 2007). The induction and preservation of SIV-specific CD4+ Tcm 
cells in vaccinated rhesus macaques have been associated with better survival and slow 
disease progression following challenge from either SIV or SHIV (Sun et al., 2005; Letvin et 
al., 2006, Manrique et al., 2008). Furthermore, the presence of SIV specific CD8+Tcm has 
been shown to also correlate with delayed SIV disease progression (Vaccari et al., 2005; 
Sun et al., 2006).  
An effective vaccine should therefore induce the differentiation of long-lived Tcm cells which 
are housed in lymphoid organs. These cells are involved in the replenishment of effector T 
cells and Tem cells. These cells produce high levels IL-2 and the ability to divide and 
differentiate rapidly into effector cells (Kaech et al., 2002; Esser et al., 2003).  Similar to 
naive T cells, Tcm cells constitutively express CCR7 and CD62L due to their ability to enter 
and exit secondary lymphoid tissues (Sallusto et al., 2002). However unlike naive T cells, 
Tcm cells are antigen experienced and have been activated by specific antigenic epitopes 
via TCRs. Therefore, Tcm have the ability to rapidly identify specific previously encountered 
antigens and upon re-emergence of the antigen these cells produce IL-2 which enables 
rapid proliferation. Tcm cells have the ability to rapidly differentiate and replenish existing 
populations of effector and Tem cells according to widely accepted models of T cell 
differentiation.  
In addition, the vaccine should also generate effector Tem cells which are found surveying 
the peripheral blood and produce antiviral cytokines such as IFN-γ and TNF-α at the sites of 
infection (Kaech et al., 2002). These cells lack the ability to re-enter lymphoid tissues 
(CCR7-) but instead express chemokines such as CCR5 and CXCR3 required for homing to 
mucosal and inflamed tissues at the site of infection where they are involved in robust 













capacity to proliferate and therefore produce relatively small levels of IL-2 but instead 
express high levels of Th1 and Th2 anti-viral cytokines (IFN-γ, TNF-α) and cytolytic enzymes 
(granzymes and perforin) (Sallusto et al., 2002)  
 
4.1.2. Aim of study 
 
It has previously been demonstrated that SAAVI MVA-C and Pr55 Gag virus-like particle 
(VLP) based on HIV-1 subtype C, induced Gag-specific responses in Chacma baboons  by 
IFN-γ ELISPOT assay measurements (Chege et al., 2008a). Chacma baboons, primed with 
pTHgag DNA and boosted with Pr55 Gag VLPs (Chege et al., 2008b) have also been shown 
to induce humoral and cellular responses specific to HIV-1 Gag. Collectively, the results 
highlight that both these vaccination strategies designed by the HIV Vaccine Development 
group at UCT are indeed capable of inducing specific T cell responses (and some humoral 
response) to HIV-1. However, there was a need to further investigate the ability of these 
vaccines to induce durable HIV-1 specific memory T cell responses. In addition, the relative 
distribution of vaccine specific T cell memory phenotypes induced by these vaccines needed 
to be determined as this is a measure of the level of protection induced by the vaccines in 
question.  
The availability of flow cytometry facilities and expertise at UCT have allowed for the further 
investigation of these T cell responses measured in PBMCs of vaccinated Chacma baboons. 
The aim of this chapter was to investigate the distribution and durability of vaccine specific 
memory T cell responses induced by the SAAVI MVA-C/VLP and DNA/VLP prime boost 
vaccine modalities in the peripheral blood of Chacma baboons by flow cytometry analysis. 
4.2. Specific objectives 
 
4.2.1. Investigate the vaccine specific T cell memory phenotype distribution in Chacma 
baboons vaccinated with SAAVI MVA-C/VLP and DNA/VLP prime/boost vaccine regimens, 
















4.3. Materials and methods 
4.3.1 Samples and vaccination schedule 
 
Cryopreserved PBMCs isolated from Chacma baboons that received two different 
vaccination regimens were used in this study. Baboons were vaccinated with either SAAVI 
MVA-C/VLP or DNA/VLP in prime/boost.  Aliquots of cyropreserved PBMCs from vaccinated 
baboons at various time-points throughout both vaccination schedule (Figure 4.2) were used 
to investigate the vaccine-specific memory phenotypes.  
Animals vaccinated with SAAVI MVA-C/VLP vaccination regimen (Group A) received SAAVI 
MVA-C prime at week 0 and the VLP boost at week 12. Animals that were vaccinated with 
the DNA/VLP vaccine regimen (Group B) received three DNA prime immunisations at weeks 
0, 4 and 8. These animals were then boosted with to VLP immunisations at weeks 51 and 
53.  Samples from a third control group of animals that were not primed by any vaccinations 
and only received VLP boosts (Group C) were also included for comparative analysis.   
Samples from Group A were selected for analysis just before the animals received the prime 
vaccination with SAAVI-MVA-C (baseline), one week following vaccination (week 1), twelve 
weeks following prime and before VLP boost was administered (week 12), four weeks 
following boost (week 16) and finally 20 weeks following the VLP boost (week 36). 
Samples Group B were selected for analysis just before the animals received the first DNA 
prime (baseline) and at eight weeks following this (week 16) were used in this study. 
Samples from twelve weeks after the second DNA prime and before the first VLP boost was 
administered (week 12) were also used. In addition, samples from the day of the first VLP 
boost (week 51), three weeks after the first VLP boost (week 55), eight weeks after the first 
VLP boost (week 63), two weeks after the second VLP boost (week 65) and finally 6 weeks 
following the second VLP boost (week 71).  Samples from Group C were selected for 















Figure 4.2. Immunisation schedule and samples selected for analysis from various time-points 
during vaccination with SAAVI MVA-C/VLP and DNA/VLP in prime-boost and VLP only. 
Samples from Group A were selected at the following time points, Wk0 (just before the animal 
received the first prime, blue arrow), Week 1, Week 12 (just before the animal received the VLP 
boost, red arrow), Week 16 (4 weeks after VLP boost) and Week 36 (20 weeks after VLP boost). 
Samples from Group B were selected at Week 0 (just before the animals received the first of three 
DNA prime vaccinations, green arrows), Week 16 (8 weeks after the last DNA vaccination), Week 51 
(just before the first VLP boost, red arrow), Week 55, Week 63 (just before the second VLP, red 
arrow), Week 65 and Week 71. Samples from matched time-points were selected from Group C at 
Week 51 (just before the first VLP boost, red arrow), Week 55, Week 63 (just before the second VLP, 
red arrow), Week 65 and Week 71. 
 
4.3.2. Selection of co-stimulatory antibodies 
 
The detection of cytokine producing cells is essential to achieve the aim of quantifying the 
extent of vaccine induced memory immune responses. It has been well established that 
cytokine production to vaccine specific antigens can be enhanced by including co-
stimulatory molecules to overcome activation thresholds in vitro (Waldrop et al., 1998). As 
such, it was necessary in this study to determine which combination of co-stimulatory 
molecules was required to ensure optimal vaccine-specific cytokine detection in this study. 
 Co-stimulatory antibodies such as purified anti- CD28 and CD49d have been found to 
enhance the level of cytokine production when PBMCs are stimulated with peptides such as 
vaccine specific Gag pools. In this case, the CD28 marker is integral in delineating memory 
in T-cells as part of the CD28/CD95 memory panel. T cells have limited CD28 receptors and 
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when the co-stimulatory antibody purified anti-CD28 is added to cells (as part of stimulation) 
there are no longer sufficient receptors for the binding of CD28-flourochrome (mAb) during 
the staining process. 
4.3.2.1. The effect of purified anti-CD28 co-stimulatory antibodies on CD28 
surface receptors   
 
It was necessary to determine if the manufacturer’s recommended concentrations of purified 
anti-human CD28 Abs had the potential to block detection of surface CD28 on baboon 
PBMCs. Three clones of anti-human CD28 co-stimulatory antibodies from three different 
sources were available and the aim of this experiment was to determine which one would 
have the least effect in blocking the detection of CD28 molecules on the surface of cells. To 
determine which clone and the optimal concentration of anti-CD28 co-stimulation antibodies 
to be used to augment the production of vaccine specific (Gag) cytokines, one aliquot of 
thawed PBMCs from an unvaccinated animal (B664) was incubated in the presence of the 
following purified anti-human CD28 antibodies (pCD28):      
 pCD28 (clone CD28.2-BD) in two-fold serial dilutions starting from 1ug/ml 
(manufacturer’s recommended concentration)    
 pCD28 (clone CD28A-Mabtech) in two-fold serial dilutions starting from 0.1ug/ml 
(manufacturer’s recommended concentration)  
 pCD28 (clone E59- Merck) in two-fold serial dilutions starting from 1ug/ml 
(manufacturer’s recommended concentration) 
On average 0.5 x106 cells per each reaction were incubated in the presence of the above 
for 30-40 minutes before surface staining for ViViD, CD3 APCCy7, CD4PECy5.5, CD8 
QDot605, CD95 APC and CD28 FITC as per protocol outlined in chapter 2. The relative 
frequency of the respective cell populations were determined using FlowJo analysis. 
4.3.2.2. The selection of purified anti-CD28 clones to augment cytokine 
production and to minimize blockade of surface CD28 detection 
 
The effect of the various clones of purified anti- CD28 co-stimulatory antibodies were 
examined by stimulating PBMCs from a post vaccination time-points for 16 hours with the 















Table 4.1 Setup of stimulation and co-stimulation of PBMCs to investigate the selection of anti-
CD28 clones 
 
All stimulations were set in a humidified 37°C incubator with 5% CO2 atmosphere. After the 
first 2 hour of incubation, BFA was added to all cells. The cells were then stained for viability 
(ViViD), surface markers (CD3 APCCy7, CD4 PECy5.5, CD8 QDot605, CD28 FITC and 
CD95 APC) and intracellular cytokines (IFN-γ, TNF-α and IL-2 multiplexed on PE) as per 
protocols outlined above. The relative frequencies of cytokines expression and CD28FITC 
expression was determined using FlowJo analysis.  
4.3.3 Evaluation of vaccine specific memory responses 
 
Revived and rested PBMCs were stimulated for 16 hour with a pool of Gag peptides and 
subsequently stained according to the staining protocols outlined in chapter 2. The cells 
were stained with a panel of flow cytometry antibodies (Table 4.1) to evaluate vaccine 
specific T cell memory phenotypes. In summary, cells were stained with the following 
antibody markers: ViViD to limit the analysis to viable cells prior to staining for the surface 
markers CD3 APCCy7, CD4PECy5.5, CD8 Qdot605, CD28 FITC and CD95 APC. The cells 
were permeabilised for intracellular staining and then stained for intracellular markers of 
cytokines (IL-2, TNF-α and IFN-γ which were multiplexed on PE). The stained cells were 
then fixed using 1x BD CellFIX (BD BioScience). The cells were then transferred to FACS 







 Stimulant Co-stimulant(s) 
SEB only SEB  NONE 
Gag only Gag-C peptides  NONE 
Gag+CD28 Gag-C peptides  purified anti-CD28  













Table 4.2 Design of the seven colour flow cytometry panel used to investigate the vaccine 
specific cytokine production and memory distribution of T cells isolated from the PBMCs of 
Chacma baboons. 
Laser Detector(nm) Fluorochrome Marker Rationale 
Blue 488nm B515 FITC CD28 Memory marker 
Green 532nm G710 PECy5.5 CD4 T cell lineage marker 
Green 532nm G560 PE IL-2, IFN-γ and TNF-α Cytokine production 
Red 640nm  R 780 APCCy7 CD3 T cell lineage marker 
Red 640nm R 660 APC CD95 Memory marker 
Violet 407nm V605 QDot605 CD8 T cell lineage marker 
Violet 407nm V450 ViViD  T cell viability maker 
 
4.3.3.1. Data Acquisition and storage  
 
The cells were analysed using the BD Fortessa. Voltages were setup using previous panels 
and adjusted accordingly during the acquisition of compensation beads and initial baboon 
PBMC samples. The data was acquired using BD Cell Diva acquisition software (BD 
Bioscience) and was set to analyse 250 000 events per sample. The data was stored on 
portal USB memory drives and saved on compact discs.   
4.3.3.2. Data analysis and gating strategy 
 
The data was analysed using FlowJo prior to the generation of a compensation matrix. The 
gating strategy used is represented in Figure 4.3. In summary, the data was first validated by 
comparing the analysis of the cells over time (SSC vs. Time). Only cells that were analysed 
by the flow cytometer as part of a continuum were gated for further analysis. To minimize 
false-positives, the forward scatter height (FSC-H) was then compared to forward scatter-
area (FSC-A) to identify cells that moved through the laser as singlet cells. Lymphocytes 
were then identified by analyzing the relative granularity and size of the singlet cells by 
comparing the side scatter (SSC) and FSC. Viable, CD3+ T-cells were then gated on by 
comparing the viability maker on the pacific blue channel and CD3 marker on the APC.Cy7 
channel. These cells were then separated into CD4+ and CD8+ cells by comparing the 
PECy5.5 and Qdot605 channels respectively. The total number of CD4+ and CD8+ cytokine 
producing was then determined. The net vaccine specific (Gag) cytokine response was 
considered a positive response if it was at least twice the background and greater than the 
cut-off value of 0.01. The background was deducted for the Gag responses to generate a net 













analysed such that the memory markers CD28 and CD95 were used to determine the 
relative frequencies of each memory phenotype.  
4.3.3.3. Statistical analysis 
 
The CD4+ and CD8+ cytokine responses were compared amongst groups of animals 
vaccinated with MVA/VLP, DNA/VLP and VLP only using non-parametric one way ANOVA 
(Kruskal Wallis) followed by Dunn’s multiple comparison. The mean and standard deviations 
of cytokine responses and memory T cell phenotype distribution were also assessed. All 
statistic analysis was performed using Graph Pad Prism version 6.00 for Windows 























Figure 4.3 Gating strategy used to determine the vaccine specific cytokine response and T cell memory phenotypes. Cells from baboons were 
stimulated with Gag, SEB and R10 media only (unstim.). Time gates were plotted for each laser. In the case of CD8 QDot605 shown here, time gates were 
also used to exclude artefacts or aggregates (if any). Singlet gates based on forward scatter height (FSC-H) and forward scatter area (FSC-A) were used to 
exclude doublet cells. Lymphocytes were gated based on the relative size and granularity of the cells and plotted as FSC versus side scatter (SSC). Live cells 
are gated on ViViD negative populations. Then, CD3+ cells were gated using cytokine expression to confirm the CD3+ population. CD4+ and CD8+ T cells 
were identified. The expression of cytokines were then determined. The net vaccine specific (Gag) cytokine response was considered a positive response if it 
was at least twice the background and greater than the cut-off value of 0.01% and contained >25 events in total. The background was deducted for the Gag 















4.4.1. Selection of co-stimulatory antibodies 
4.4.1.1. The effect of purified anti-CD28 co-stimulatory antibodies on CD28 
surface receptors   
 
To determine which of the three commercially available clones of purified anti-CD28 
(pCD28) had the potential to block the detection of surface CD28 on PBMCs isolated from 
Chacma baboons, PBMCs were incubated with individual clones of pCD28 prior to staining 
for the flow cytometry analysis. 
The frequency of CD4+ CD28+ T cells were maintained at 90-95% in the presence of pCD28 
clones CD28.2 (BD Bioscience) and at 50-60% when in the presence of pCD28 clone 5E9 
(Merck) at concentrations below 1ug/ml and 0.1ug/ml respectively (Figure 4.4). The 
frequency of CD28+CD28+ T cells were also maintained at 90-95% in the presence of 
clones CD28.2 (BD Bioscience) and at 50-60% when in the presence of pCD28 clone 5E9 
(Merck) at concentrations below 1ug/ml and 0.1ug/ml respectively (Figure 4.4). These data 
suggest that at these concentrations pCD28 clones did not compromise the detection of 
surface CD28 receptors on CD4+ and CD8+ T cells during flow cytometry analysis and 
therefore these optimal concentrations which were recommended by the manufacturer were 
used throughout this study.  
4.4.1.2. The selection of purified anti-CD28 clones to augment cytokine 
production and to minimize blockade of surface CD28 detection 
 
A suitable co-stimulatory molecule should induce T cell specific activation in vitro to enhance 
the expression and hence detection of rare cytokine events by flow cytometry analysis. In 
addition, the co-stimulatory molecule should be present at optimal concentrations without 
blocking the detection of CD28 molecules. The aim of this experiment was to determine 
which clone of pCD28 induced the highest proportion of cytokines for flow cytometry analysis 
of vaccine specific T cell memory. The frequency of conjugate bound CD28 FITC for each 
reaction was also determined by flow cytometry analysis. 
Stimulation of PBMCs in the presence of purified anti- CD28 (clone CD28.2) purchased from 
BD and pCD49d induced 0.34% cytokine production in CD4+ T cells and  0.31% of 
cytokines in the CD8 T cell compartment (Figure 4.5A). The frequency of surface conjugate 
bound CD28 decreased by about 20-25% in both CD4 and CD8 T cells (Figure 4.5B).  













of the CD28 receptor (Figure 4.5B), and 0.3% of CD4+ T cells and 0.26% of CD8+ T cells 
produced cytokines (Figure 4.5A).  
The purified anti-CD28 antibody purchased from Mabtech only induced 0.27% and 0.18% of 
cytokine production from CD4 and CD8 T cells respectively (Figure 4.5A). The frequency of 
CD28+ cells diminish to 49.3% and 39.3% in CD4+ and CD8+ T cells respectively that have 
been stimulated in the presence of pCD28 purchased from Mabtech (Figure 4.5B). The 
purified anti-CD28 purchased from Merck was therefore used to augment cytokine 
production in this study. Stimulation in the presence of this antibody did not block the 
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Figure 4.4 Frequency of surface CD28+ populations after pre-incubation with various clones of 
purified anti-CD28 during stimulation. Cryopreserved PBMCs from an unvaccinated animal was 
pre-incubated with A) pCD28 clone CD28.2, B) p28 clone 5E9 and C) pCD28 clone CD28A at serial 
dilutions (concentration). The cells were gated on lymphocyte populations based on SSC and FSC 
properties and further gated on viable (ViViD-) CD3+ populations. Graphs show the frequency of 














Figure 4.5. The net cytokine expression and frequency of surface CD28 FITC after stimulation of PBMCs in the presence of various clones of 
purified anti-CD28. Cryopreserved PBMCs from one week after vaccination with SAAVI-MVA C (animal B646) were stimulated with Gag peptide pools in the 
presence of purified anti-CD28 from BD, Merck and Mabtech together with purified anti-CD49. PBMCs stimulated with Gag peptide pools only and SEB only 
were also included. A) The bar graphs represent the net expression (background of 0.01% and 0.07% excluded from CD4+ and CD8+ responses 
respectively) of cytokines (multiplex of IL-2, IFN-γ and TNF-α on PE conjugate) when PBMCs were stimulated with Gag and various clones of the co-
stimulants CD28 clone CD28.2 (CD28 BD) purchased from BD BioScience, CD28 clone E59 (CD28 Merck) purchased from Merck and CD28 clone CD28A 
(CD28 Mabtech), purchased from Mabtech together with CD49d. In the case of CD28 clone CD28.2 (CD28 BD), a control without CD49d (Gag only) was 
included. B) The bar graphs represent the frequency (%) of CD28 FITC CD4+ (red bars) and CD8+ (blue bars) cell populations after stimulation with a variety 















4.4.2. Evaluation of vaccine specific memory responses 
 
4.4.2.1. Comparison of vaccine (Gag) specific cytokine production assessed in 
PBMCs from baboons vaccinated with MVA-VLP, DNA-VLP prime-boost 
regimens or VLPs only. 
 
Flow cytometry analysis was used to quantify the vaccine specific (Gag specific) cytokine 
responses induce by the MVA/VLP, DNA/VLP and VLP only groups of animals. The peak 
CD4+ and CD8+ cytokine responses for n=3 animals in the MVA/VLP vaccine regimen was 
observed 4 weeks after the VLP boost was administered. The mean of the net cytokine 
response at peak response were 0.21%± 0.01 and 0.24% ± 0.05 (mean± standard deviation) 
in the CD4+ and CD8+ T cells respectively. The cytokine response to Gag in these animals 
decreased after the peak at week 36 (0.13% ±0.03 and 0.15±0.04 in CD4+ and CD8+ 
respectively), but these responses were higher than those observed before the peak 
response. The peak CD4+ and CD8+ cytokine response  for the DNA/VLP group n=5 was 
observed at week 55 (0.17%± 0.04 and 0.07%± 0.01 in CD4+ and CD8+ T cells 
respectively) which was also 4 weeks after receiving the first VLP boost (Figure 4.7). The 
cytokine responses also decreased in the CD4+ compartment of animals at week 63, 8 
weeks after the peak response, but appeared to be maintained at a higher level (0.07%± 
0.01) than prior to VLP boosting. In the CD8+ population, the peak response was not high 
compared to the CD4+ population, but it appears that the second VLP boost received at 
week 63 helped maintain a cytokine response at an average of 0.05% ± 0.009 (Figure 4.7).   
The peak CD4+ and CD8+ responses for both vaccine regimens were observed 4 weeks 
after the first VLP was administered. The peak CD4+ cytokine response in the MVA/VLP 
group (n=3) was significantly higher (Adjusted P value= 0.037) compared to the VLP only 
group (n=2) and higher (although not statistically significant) compared to that of the 
DNA/VLP group (n=5).  The peak CD8+ cytokine response in the MVA/VLP was significantly 
higher (Adjusted P value= 0.038) compared to the DNA/VLP group. However, the peak 
CD8+ cytokine responses in both vaccinated groups were higher compared to the VLP only 
group (although not statistically significant).  
At the final time-point (Week 36) analysed in the MVA/VLP group, the mean CD4+ and 
CD8+  cytokine responses were significantly higher (Adjusted P value= 0.006 and 0.007 
respectively) compared to the final time-point assessed in the DNA/VLP group (Week 71). 
However, the final CD4+ CD8+ cytokine responses in both vaccinated groups were higher 
compared to the final time-point assessed in the VLP only group (Week 20) (although not 













                                                                                                                                            
Figure 4.6.  Representative pseudo-colour dot plots showing the flow cytometry analysis of vaccine specific cytokine expression (Gag) in CD4+ 
and CD8+ T cells in baboon 447 (SAAVI MVA-C/ VLP group). Cryopreserved PBMCs from various time-points during the vaccination schedule were 
stimulated with either vaccine specific Gag peptide pools (Gag), SEB or no antigen. The cells were gated on lymphocyte populations based on their SSC and 
FSC properties. Viable (ViViD negative) CD3+ T cells were then gated into either CD4+ or CD8+. The expression of cytokines IL-2, IFN-γ and TNF-α 
multiplexed onto PE were determined for both CD4+ and CD8+ T cells.  The dot plots show cytokine expression relative to the negative controls in which cells 
were incubated in R10 media only (No Ag, unstim.) and positive control in which cells were stimulated with SEB. The net vaccine specific (Gag) cytokine 
response at each time-point was considered a positive response if it was at least twice the background (No Ag, unstim) and greater than the cut-off frequency 
value of 0.01% and greater than 25 events. Representative time-points shown include baseline (week 0), peak response (week 16, four weeks after VLP 














Figure 4.7. Vaccine specific (Gag) cytokine response in CD4+ and CD8+ T cells during 
vaccination regimens.  Graphs depict the net cytokine expression in T cells for baboons that 
received either A) SAAVI MVA-C (green arrows) and VLP (black arrows), B) DNA (orange arrows) 
and C)VLP(black arrows) or VLP (black arrows) only. Net cytokine responses at each time-point were 
determined by subtracting the background from the unstimulated control. The net vaccine specific 
cytokine response was considered positive if it was at least twice the background (No Ag, unstim) and 













4.4.2.2. Distribution of vaccine (Gag) specific T cell memory phenotypes in 
PBMCs from baboons vaccinated with MVA-VLP or DNA-VLP prime-boost 
regimens or VLPs only. 
 
The vaccine specific (cytokine producing cells in response to Gag) were then further 
analysed using CD28 and CD95 markers to determine the distribution of memory 
phenotypes in these vaccine specific cells.  
The naïve CD4+ and CD8+ T cell populations were excluded from the statistical analysis. As 
a result, the distribution of effector and central memory phenotypes were determined in 
animals from the MVA/VLP, DNA/VLP and VLP only vaccine regimen. 
Vaccination with MVA/ VLP appears to skew Gag specific CD4+ T cell responses towards 
the central memory phenotype (mean distribution ± standard deviation = 84.23% ± 12.42) at 
peak response (week 16) compared to the effector memory phenotype (25.47% ± 7.33) 
(Figure 4.8). A similar distribution of the memory phenotypes was maintained 20 weeks after 
the vaccination with a predominately Tcm phenotype (80.4% ± 13.30) compared to the Tem 
phenotype (28.47%± 7.33). In these animals, Gag specific CD8+ T cell responses were 
more evenly distributed between Tcm and Tem phenotypes at peak response (58.9% ± 
21.01 and 41.03%± 20.90 respectively) and at the final time point (20 weeks after 
vaccination), the mean distribution of Tcm was 55.6% ±13.58 compared to Tem which 
contributed to 44.40% ± 13.58 of the Gag-specific CD8+ T cell responses.  
A similar memory distribution profile of Gag-specific CD4+ cells in DNA/VLP vaccinated 
animals was observed at peak response during which responses were skewed towards Tcm 
phenotype (91.17% ± 21.01) and only a small percentage of responsive cells were 
characterised as the Tem phenotype (6.6% ± 0.87) (Figure 4.9).  This skewing of CD4+ T 
cells towards a Tcm phenotype was maintained 16 weeks post vaccination with a mean of 
88.17% ±3.62 of the responsive cells having a Tcm phenotype and 11.83%±3.62 having a 
Tem phenotype. However, Gag-specific CD8+ cells were distributed in a different manner 
between Tcm (44.43% ± 15.65) and Tem (55.57± 15.65) phenotypes at peak response with 
Tem phenotype contributing to almost 10% more of the responsive cells whereas the 
distribution of CD8+ cytokine producing cells 16 weeks post vaccination were distributed 
















Figure 4.8. Memory phenotype distribution of Gag-specific T cells following vaccination with SAAVI MVA-C/VLP in prime-boost. Cryopreserved 
PBMCs from vaccinated Chacma baboons were examined for Gag-specific memory T cells. Cytokine producing CD4+ and CD8+ T cells were delineated into 
central (Tcm) and effector (Tem) memory cells based on CD28 and CD95 expression.  A) Representative flow cytometry plots of the memory profile of total 
CD4+ (upper panel) and CD8+ (lower panel) T cells shown as density p lots with overlaid Gag-specific total cytokine producing cells (red and green dots for 
CD4+ and CD8+ T cells respectively) in a vaccinated animal (B447) at peak response (Week 16). B) Proportion of Gag-specific CD4+ (upper panel) and 
CD8+ (lower panel) T cells at peak response (Week 16, 4 weeks after VLP vaccination) and the final time-point assessed (Week 36).  Data are depicted as 
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Figure 4.9. Memory phenotype distribution of Gag-specific T cells following vaccination with DNA/VLP in prime-boost. Cryopreserved PBMCs from 
vaccinated Chacma baboons were examined for Gag-specific memory T cells. Cytokine producing CD4+ and CD8+ T cells were delineated into central (Tcm) 
and effector (Tem) memory cells based on CD28 and CD95 expression.  A) Representative flow cytometry plots of the memory profile of total CD4+ (upper 
panel) and CD8+ (lower panel) T cells shown as density plots with overlaid Gag-specific total cytokine producing cells (red and green dots for CD4+ and 
CD8+ T cells respectively) in a vaccinated animal (B660) at peak response (Week 55). B) Proportion of Gag-specific CD4+ (upper panel) and CD8+ (lower 
panel) T cells at peak response (Week 55, 4 weeks after VLP vaccination) and the final time-point assessed (Week 71).  Data are depicted as mean± 













4.5  Summary of key findings 
 
This study shows that two out of three available clones of co-stimulatory pCD28 antibodies 
can be used in combination with pCD49d antibodies to augment the production of Gag-
specific cytokine production by CD4+ and CD8+ T cells. These clones include CD28.2 and 
CD28A from BD Bioscience and Merck respectively, do not block the detection of surface 
CD28 by surface staining for flow cytometery analysis. However the E59 clone of pCD28 
purchased from Mabtech, reduces the detection of CD28 and was therefore not used in this 
study. 
The major findings of this study demonstrate that vaccination with SAAVI MVA-C and VLP 
prime boost induces the production of Gag-specific cytokines in CD4+ and CD8+ T cells 
from the peripheral blood of Chacma baboons. The peak response was observed at week 
16, four week following the VLP boost vaccination and the CD4+ peak response was 
significantly higher compared to the VLP only group. At peak response, the CD8+ responses 
were significantly higher in the MVA/VLP group compared to the DNA/VLP group. This 
response was maintained at levels lower than the peak at week 36. In addition, vaccination 
with DNA/VLP prime boost induced cytokine producing CD4+ and CD8+ T cells in response 
to Gag stimulation in peripheral blood from Chacma baboons. The peak cytokine responses 
were observed at week 55, four weeks after the animals received the first VLP boost 
vaccination. This response was still detectable at week 71. However, CD4+ and CD8+ were 
significantly lower compared to the responses observed at the final timepoint (Week 36) in 
animals vaccinated with MVA/VLP. 
Vaccination with SAAVI MVA-C/VLP induced Gag-specific CD4+ and CD8+ T cell responses 
that were skewed towards the Tcm phenotype at peak response. Gag-specific CD4+ cells 
persisted for 20 weeks post vaccination and were predominantly central memory T cells. 
Vaccine specific CD8+ T cells were also observed at this stage and comprised around 40% 
of total vaccine specific memory. Further, the DNA/VLPs prime boost regimen induced 
quantifiable Gag-specific CD4+ and CD8+ responses which persisted for 16 weeks after the 
peak response. These responses were comprised predominately of CD4+ Tcm and both 
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The ability of candidate HIV-1 vaccines to induce the differentiation of long-lived, functional 
and vaccine specific T cell memory recall responses is a measure of vaccine immune 
response and durability. Both central memory and effector memory T cells work in synergy 
to induce secondary responses to antigen (Sprent and Surh, 2002). In general, Tcm cells 
provide a pool of antigen specific precursor cells capable of rapid proliferation in lymphoid 
tissues to generate and replenish effector or effector memory cells (Sallusto et al., 2004) 
whilst Tem cells are associated with a robust effector response at the site of infection or 
pathogen entry (Lefrancois and Masopust,  2002). 
One of the aims of this study was to investigate various anti-human antibody markers of T 
cell function and maturation to select a suitable combination of markers which can be used 
to detect T cell memory phenotypes in peripheral blood mononuclear cells (PBMCs) from 
Chacma baboons. In addition, this study aimed to determine the suitability of the selected 
combination for use in multicolour flow cytometry. The key aim of this study was to develop a 
multi-parameter flow cytometry panel to assess vaccine specific T cell memory response in 
PBMCs from Chacma baboons. These panels were then used to assess the vaccine specific 
memory recall responses induced by the candidate SAAVI MVA-C/VLP and DNA/VLP 
prime-boost vaccination regimen in Chacma baboons by flow cytometry.   
5.2. Evaluation of commercially available clones of anti-human T cell 
memory markers for cross-reactivity with baboon PBMCs 
Several clones of anti-human antibody markers were evaluated for cross-reactivity using 
cryopreserved PBMCs isolated from healthy, unvaccinated Chacma baboons.  Cross-
reactivity was confirmed for various clones of T cell phenotype markers (CD3, CD4, and 
CD8), maturation markers (CD28, CD27, CD95, CD45RA) and functional capacity (IL-2, 
TNF-α, IFN-γ). However, anti-human marker of CCR7 (clone 150503), the chemokine 
receptor commonly used in combination with CD45RA in human and rhesus macaque (Mooij 
et al., 2009) studies to delineate T cell memory phenotypes did not cross-reactively stain 
PBMCs isolated from Chacma baboons despite staining cells at the recommended 
temperature (37°C). This marker was therefore excluded from memory marker panels to 
investigate T cell memory phenotype distribution in Chacma baboons.  Furthermore, CCR5 
(clone 3A9) did not appear to be cross-reactive in Chacma baboon PBMCs.  This marker is 
commonly used to investigate the level of T cell activation and HIV-1 target cells 
(CD4+CCR5+) in rhesus macaques (Liu et al., 2009) and humans. The expression of CCR5 













Chemokine receptor detection sensitivity is reduced during the freeze-thawing of 
cryopreserved PBMCs. Other findings indicate that the detection of surface CCR5 is reduced 
in cryopreserved PBMCs compared to freshly isolated samples in human studies (Costantini 
et al., 2003). It is hypothesised that this reduction in the surface expression of CCR5 is to be 
due to molecular shedding of the CCR5 receptors during the cryopreservation process itself 
(Costantini et al., 2003). The length of cryopreservation and liquid nitrogen storage also 
impacts negatively on the detection of chemokine receptor markers (Tollerud et al., 1991). It 
is recommended by the manufacturers that staining with these chemokine receptors should 
be performed on freshly isolated T cells instead. In addition, it is also possible that genetic 
differences between rhesus macaques and Chacma baboons could also account for the 
limited recognition of the CCR5 molecule in this study.  
In this study, the optimal staining temperature was also determined by staining 
cryopreserved PBMCs from healthy Chacma baboons at either room temperature, 37 
degrees Celcius or on ice. Since a higher level of non-specific fluorescence was observed at 
37ºC compared to that at room temperature and the lowest level of background staining was 
observed at room temperature (+/- 23 to 27 ºC) this study suggests that baboon PBMCs 
should be stained at room temperature. This was in keeping with previous flow cytometry 
analysis performed using baboon PBMCs by other groups within the Division of Virology, 
IIDMM, and UCT.  
5.3. Selection of suitable T cell memory markers for inclusion in a flow 
cytometry panel to investigate memory phenotypes in baboon PBMCs.  
Four colour flow cytometry antibody panels were used to investigate which combination of 
memory markers was most suitable to include in a final panel for the analysis of memory 
responses in PBMCs isolated from baboons. In this study, CD45RA and CD95 allowed for 
the separation of CD4+ and CD8+ naive T cells (Tnaive: CD45RA+CD95-) and memory T 
cells (CD45RA-CD95+) but clear Tcm and Tem populations were not distinguishable.  The 
addition of either a co-stimulatory molecules (such as CD28 or CD27) or CCR7 would be 
useful in this regard (Sun et al., 2005). However, CCR7 was not found to be cross-reactive 
with cryopreserved PBMCs isolated from Chacma baboons and a minimum of two markers 
could be accommodated in this panel. The CD27 and CD95 markers separated naive T cells 
(CD27+ CD95-) from Tcm (CD27+CD95+) and Tem (CD27-CD95+) but the separation was 
not as clear compared to the CD28 and CD95 combination.  Using the combination of CD28 
and CD95, the memory phenotypes were defined as central memory (Tcm; CD28+CD95+) 
and effector memory (Tem; CD28-CD95+) populations with the naïve T cells being defined 













inclusion in a flow cytometry panel to further investigate T cell memory phenotypes in 
PBMCs from Chacma baboons. 
5.4. The characteristics of T cell memory phenotypes delineated by the 
selected combination of markers to determine the suitability of these 
markers for inclusion in a flow cytometry panel using baboon PBMCs. 
The results of this study show that in combination, anti- CD28 and -CD95 antibodies provide 
a distinct separation of total effector and central memory T cells from the naïve T-cell subset. 
Consistent with the findings of other studies conducted in adult rhesus macaques (Jankovic 
et al., 2003; Pitcher et al., 2002) and cynomolgus monkeys (Nadazdin et al., 2010)  the 
relative proportions of CD28+CD95+ central memory and CD28-CD95+ effector memory 
cells in peripheral blood of Chacma baboons varied in the CD4+ and CD8+ compartments. A 
larger proportion of Tcm cells were observed in the CD4+ compartme t compared to the 
CD8+ T cells while the Tem were the primary CD8+ memory phenotype. There was no 
significant variation in the frequencies of memory subpopulations in both CD4+ and CD8+ T-
cells. However, there were a higher proportion of Tem cells in the CD8+ compartment 
compared to the CD4+ T-cells while the opposite was true for Tcm cells. This observation 
was also found in other pilot studies using baboon PBMCs conducted within the Division of 
Medical Virology.  
Table 5.1. Comparison of the frequency (%) of CD4+ and CD8+ memory T cell 
populations amongst non human primates.   
 
A. Sun et al. (2005); Jankovic et al. (2003); Pitcher et al. (2002); B. Nadazdin et al., 2010; C. Findings 
of current study (Chapter 3) 
 
The Tcm and Tem phenotypes delineated by the selected anti- CD28 and -CD95 antibody 
markers were then further characterised in terms of level of maturation (measured as 
expression of CD45RA). These subsets were also characterised further by investigating the 
expression of the early activation marker (CD69) and the production of cytokines (IL-2 and 
IFN-γ) in response to SEB stimulation.  The Tcm and Tem subsets exhibited the expected 
functional and phenotypic characteristics, similar to those previously observed for T cells 
Non human primate CD4+ (%)  CD8+ (%) 
T naive Tcm Tem  T naive Tcm Tem 
Rhesus macaqueA 25-30 30-60 15-20  25-30 15-20 50-70 
Cynomolgus monkeyB 30-50 30-50 10-15  30-40 20 50-60 













from normal rhesus macaques (Pitcher et al., 2002, Jankovic et al., 2003; Sun et al., 2005). 
In particular, CD45RA expression was investigated in the T cell memory phenotypes defined 
by CD28 and CD95. This isoform of CD45 was used because it is available in numerous 
clones that have been found to cross-react with non-human primate species. In contrast 
clones of CD45RO which is commonly used to delineate T cell memory populations in 
human studies, do not cross react with rhesus macaques (of Chinese origin) (Wang et al., 
2008) and cross-reactivity with Chacma baboons have not been determined. In this study, 
the expression of CD45RA was limited to CD4+ and CD8+ naive T cells and IL-2 production 
was observed primarily in CD28+CD95+ central memory CD4+ and CD8+ T cells. This 
phenotype of memory T cell has the ability to rapidly proliferate and differentiate further into 
effector or effector memory T cells upon antigen exposure, a characteristic influenced by the 
release of IL-2, a cytokine involved in the homeostatic maintenance of memory T cells 
(Sallusto et al., 2004).   
On the other hand, IFN-γ production was higher in Tem cells compared to naive and Tcm in 
the CD4+ and CD8+ compartments but was also produced by CD8+ Tcm cells. The 
production of IFN-γ is associated with the ability of CD8+ Tcm and Tem to induce a robust, 
sustained antiviral response to antigen at the level of the lymphoid tissues and mucosal 
portals of viral entry respectively.  CD69 expression was not significantly different amongst 
populations of memory and naive T cells in the peripheral blood CD4+ and CD8+ 
compartments. However, both CD4+ and CD8+ memory phenotypes appeared to express 
more CD69 compared to naive T cells in response to SEB stimulation. This indicates that the 
memory populations defined by CD28 and CD95 markers are more responsive to antigen 
stimulation compared to naive T cells, an expected outcome since naive T cells have a lower 
activation threshold compared to memory T cells (Kimachi et al., 2003) These results 
therefore indicate that the combination of anti- CD28 and -CD95 antibody markers effectively 
separate naive T cells , Tem and Tcm from each other and are suitable for inclusion in a 
multicolour flow cytometry panel for evaluation of candidate HIV vaccines in the baboon 
model.  
5.5. Optimisation of a flow cytometry panel for the investigation of 
vaccine specific memory T cell responses in PBMCs isolated from 
Chacma baboons. 
The measurement for cytokine production in response to vaccine specific antigens is a 
method employed to identify vaccine responsive cells (Jung et al., 1993). However, the 
addition of co-stimulatory molecules such as purified CD28 (Waldrop et al., 1998) and 













production. In this study, CD28 was also used as a surface T cell memory marker and the 
addition of purified CD28 during stimulation could block the CD28 surface receptors and 
reduce the detection of this marker by flow cytometry analysis. Three clones of purified 
CD28 was used as co-stimulatory antibodies in PBMCs isolated from Chacma baboons to 
determine which clone adequately augmented cytokine production without reducing the 
detection of surface CD28 markers by flow cytometry analysis. 
Clones CD28.2 (BD Bioscience) and 5E9 (Merck) of purified CD28 did not compromise the 
detection and frequency of surface CD28 receptors on CD4+ and CD8+ T cells during flow 
cytometry analysis when used at 1ug/ml and 0.1ug/ml respectively. Co-stimulation with Gag 
peptide pools and purified anti- CD28 (clones  CD28.2 and 5E9) together with pCD49d 
improved cytokine production in both CD4+ and CD8+ compared to cells which were only 
stimulated with peptide pools. However, co-stimulation of Gag-peptide pools with CD28 
(clone CD28A, from Mabtech) and CD49d  failed to augment cytokine production in CD4+ 
and CD8+ T cells compared to when cells were stimulated with Gag peptides only. Further, 
co-stimulation with this clone reduced the frequency of surface CD28 detection by flow 
cytometry analysis. This clone was therefore not used in this study. It is possible that this 
clone blocked the CD28 receptors during stimulation and fluorochrome bound anti-CD28 
antibodies could not attach to the cell surface during staining. This could explain the 
decrease in the frequency of CD28 expression during flow cytometry analysis.  
5.6. Vaccine specific T cell memory phenotype distribution in Chacma 
baboons vaccinated with SAAVI MVA-C/VLP and DNA/VLP prime/boost 
vaccine regimens  
The memory markers, anti- CD28 and -CD95 were then used to develop and optimise flow 
cytometry panels to investigate the distribution of memory T-cell phenotypes in Chacma 
baboons vaccinated with either SAAVI MVA-C prime and VLP boost, DNA prime and VLP 
boost or VLP only vaccine regimens.  This panel developed also comprised of cytokines (IL-
2, IFN-γ and TNF-α) multiplexed onto one fluorochrome (PE) for the detection of Gag- 
specific cytokine producing T cells in response to in vitro stimulation of PBMCs from 
vaccinated Chacma baboons.          
This study demonstrate that vaccination with SAAVI MVA-C and VLP prime boost induces 
the production of Gag-specific cytokines in CD4+ and CD8+ T cells from the peripheral blood 
of Chacma baboons. The peak response was observed at week 16, four week following the 
VLP boost vaccination and the CD4+ peak response was significantly higher compared to 













MVA/VLP group compared to the DNA/VLP group. This response was maintained at levels 
lower than the peak at week 36 suggesting that vaccination with MVA/VLP induces improved 
Gag-specific CD8+ responses in Chacma baboons 
In addition, vaccination with DNA/VLP prime boost induced cytokine producing CD4+ and 
CD8+ T cells in response to Gag stimulation in peripheral blood from Chacma baboons. The 
peak cytokine responses were observed at week 55, four weeks after the animals received 
the first VLP boost vaccination. This response was still detectable at week 71. However, 
CD4+ and CD8+ were significantly lower compared to the responses observed at the final 
time point (Week 36) in animals vaccinated with MVA/VLP but higher than those observed in 
animlas in the VLP only group.  
The  findings of this study indicate that vaccination with the SAAVI MVA-C/ VLP prime boost 
regimen generated Gag-specific cytokine producing CD4+ cells which persisted for 20 
weeks post vaccination and were predominantly central memory T cells. Similar distribution 
patterns of T cell memory phenotypes following vaccination were observed in the DNA/VLP 
prime boost regimen in which CD4+ T cell responses persisted for 16 weeks after 
vaccination and were skewed towards a Tcm phenotype. The skewing of vaccine specific 
CD4+ T cell responses in both vaccine regimens towards the Tcm phenotype imply that 
these vaccines have the capacity to generate CD4+ Tcm pools associated with rapid 
differentiation and replenishment of vaccine specific effector cells. Previous studies provide 
further evidence that the establishment and preservation of HIV/SIV/SHIV specific CD4+ 
Tcm pools by vaccination are important in preventing AIDS pathogenesis. Immunization with 
plasmid DNA and recombinant adenovirus SIV vaccines induced prolonged survival 
following SIV or SHIV 89.6P challenge and was attributed to the preservation of CD4+ Tcm 
cells in vaccinated rhesus macaques (Letvin et al., 2006; Sun et al., 2005, Liu et al., 2008). 
HIV-1 infected individuals on ART that were vaccinated with HIV-1 rgp160 demonstrated an 
increase in HIV-1 specific CD4+ Tcm population and improved level of survival compared to 
unvaccinated HIV-1+ patients (Gudmundsdotter et al., 2008). The importance of a vaccine 
induced pool of antigen specific CD4+ Tcm has been highlighted in previous studies 
investigating the turn-over of T cell memory populations in healthy humans. These data 
shows that CD4+ Tem cells are replaced at a faster rate than CD4+ Tcm cells and imply that 
a continuous supply of new cells is required to maintain the CD4+ Tem population to provide 
a sustained rapid effector response at the sites of infection (Macallan et al., 2004). The same 
phenomenon has been observed in SIV challenged rhesus macaques in which the gradual 













homeostatic generation of CD4+ Tem at sites of infection and correlates to disease 
progression (Okoye et al. 2007). 
In this study, vaccination with MVA/VLP also induced vaccine specific CD8+ T cells which 
were almost evenly distributed between Tcm and Tem at the peak response. Gag-specific, 
cytokine producing CD8+ cells persisted for 20 weeks post vaccination and were comprised 
of both Tcm and Tem phenotypes.  Similarly, in the DNA/VLP regimen, quantifiable Gag-
specific CD8+ responses were detected and persisted for 16 weeks after the peak response.  
These responses were both CD8+ Tcm and Tem cells. This result indicates that both 
vaccination regimens induced quantifiable CD8+ Tcm which have been associated with 
rapid proliferation in response to antigen (Wherry et al., 2003) and the maintenance of 
sustained CD8+ T cell secondary memory response which are important in controlling 
prolonged infections (Butler et al., 2011).  The presence of CD8+ Tcm has previously been 
inversely correlated to SIVmac251 replication in challenged rhesus macaques following 
prime/boost vaccination with DNA/NYVAC, suggesting that these cells are associated with 
the control of viral replication (Vaccari et al., 2005).  Acierno et al. (2006) also demonstrated 
a loss in Gag-specific CD8+ Tcm in unvaccinated rhesus macaques which progressed 
rapidly to disease compared to rhesus macaques v ccinated with DNA/recombinant pox- 
and adeno-virus vectors following SHIV challenge.  
In addition, the presence of Gag specific CD8+ effector memory T cells observed in the 
current study has also been previously associated with the control of infection by inducing 
immediate effector functions at the portals of mucosal HIV-1 entry without having to undergo 
further proliferation. In fact, Hansen et al. 2009 demonstrated that SIV challenge in rhesus 
macaques vaccinated with rhesus macaque cytomegalovirus (RhCMV) vectors, effectively 
controlled infection by generating Gag-specific CD8+ Tem biased response, particularly in 
the mucosal portals of entry. Since most HIV-1 infections are acquired via the mucosal route, 
vaccination regimens, which induce a population of available CD8+ Tem at these sites will 
be invaluable for the control of viral replication early on during infection.  In the current study 
we have identified Gag-specific CD8+ Tem in the peripheral blood of Chacma baboons 
vaccinated with either DNA/VLP or MVA/VLP and this implies that both vaccine regimens 
are capable of inducing a population of vaccine specific Tem cells. However, the functional 
quality and the distribution of these vaccine specific CD8+ Tem cells in mucosal tissues are 













In summary, this study demonstrated that both MVA/VLP and DNA/VLP vaccination 
effectively induced long-lived Gag-specific memory T cells compared to the VLP only control 
group.  
5.7. Future research 
In this study, only cryopreserved peripheral lymphocyte samples were available for analysis. 
Identifying cellular immune responses in blood alone does not adequately summarise the full 
milieu of the vaccine specific immune responses. Further assessment of lymphoid tissues 
and mucosal tissues to determine the distribution of memory T cells in response to 
vaccination was therefore not possible in this study, but can and should be done in future 
work. In addition, vaccine induced T cell activation and inflammation were not investigated in 
this study and need to be assessed in order to further characterise the safety of these 
candidate HIV-1 vaccines. In addition, the pre-existing anti-vector immune responses to the 
candidate vaccine regimens, particularly to SAAVI MVA-C need to be investigated in future 
studies. In addition, the vaccine specific cytokine responses in this study were only 
monitored for up to 20 weeks and 16 weeks post vaccination in the MVA/VLP and DNA/VLP 
groups respectively due to the limited availability of cryopreserved samples. It is therefore 
not clear whether the vaccine responses platued or if they waned over time.  Future 
experiments should therefore also include time-points beyond those examined in this study.   
Although this study was based on T cell memory responses, an ideal vaccine should be able 
to induce both T cell and B cell immune responses. It has been demonstrated in the RV144 
study that vaccines with the ability to induce non-neutralising antibodies can be protective 
(Haynes et al., 2012; Zolla-Pazner et al., 2013).  Therefore, more experiments should be 
performed to further characterise the B cell immune responses induced by these vaccine 
regimens. 
5.8. Conclusion 
In this study, anti-human antibodies which are markers of maturation and that were cross-
reactive with baboon PBMCs were identified. A suitable combination of two antibodies was 
identified and shown to be suitable for delineating T cell memory phenotypes. Used in 
combination, CD28 and CD95 were confirmed as suitable markers to delineate T cell 
memory phenotypes using PBMCs isolated from Chacma baboons. The memory T cell 
phenotypes defined by these markers had the expected maturation, functional and activation 
characteristics in terms of CD45RA, IL-2, IFN-γ and CD69 expression respectively. These 
markers were then used together with markers of viability (ViViD), T cell phenotype (CD3, 













multiparamter flow cytometry panel . This panel was then used to further investigate the 
distribution of vaccine specific T cell memory phenotypes in PBMCs isolated from Chacma 
baboons vaccinated with prime-boost regimens of either SAAVV MVA-C/VLP orDNA/VLP. 
This study also demonstrates that vaccination with SAAVI MVA-C/VLP and DNA/VLP prime-
boost vaccination regimen successfully induced functional, long-lived vaccine specific, Tcm 
and Tem in the peripheral blood of Chacma baboons and further support the use of Chacma 
baboons, a nonhuman primate model readily available in southern Africa, in HIV vaccine 
research. In addition, this study suggests that South African developed HIV-1 vaccines, 
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